Novel polypeptide, cDNA encoding the same, and use thereof

ABSTRACT

Novel polypeptides produced by a human adult brain tissue, a cell line derived therefrom, a cell line derived from human bone marrow and a human umbilical cord venous endothelial cell line; a process for producing these polypeptides; cDNAs encoding the polypeptides; fragments hybridizable selectively with the cDNA sequences; replication or expression plasmids having the cDNAs integrated thereinto; host cells transformed by the plasmids; antibodies against the above polypeptides; and medicinal compositions containing the peptides or the antibodies.

TECHNICAL FIELD

[0001] The present invention relates to novel polypeptides, a process for preparation thereof, cDNAs encoding the polypeptide, vectors containing the cDNA, host cells transformed with the vector, antibodies against the polypeptide, and pharmaceutical compositions containing the polypeptide or the antibody.

TECHNICAL BACKGROUND

[0002] Until now, when one skilled in the art intends to obtain a particular polypeptide or a cDNA encoding it, he/she generally utilizes methods by confirming an aimed biological activity in a tissue or in a cell medium, isolating and purifying the polypeptide and then cloning a gene or methods by “expression-cloning” with the guidance of the biological activity. However, physiologically active polypeptides in living body have often many kinds of activities. Therefore, it happens increasingly that after cloning a gene, the isolated gene is found to be identical to that encoding a polypeptide already known. In addition, some factors could be generated in only a very slight amount and/or under specific conditions and it makes difficult to isolate and to purify the factor and to confirm its biological activity.

[0003] Recent rapid developments in techniques for constructing cDNAs and sequencing techniques have made it possible to quickly sequence a large amount of cDNAs. By utilizing these techniques, a process, which comprises constructing cDNA library using various cells or tissues, cloning the cDNA at random, identifying the nucleotide sequences thereof, and expressing novel polypeptides encoded thereby, is now in progress. Although this process is advantageous in that a gene can be cloned and information regarding its nucleotide sequence can be obtained without any biochemical or genetic analysis, the target gene can be discovered thereby only accidentally in many cases.

[0004] The present inventors have studied a cloning method to isolate genes encoding proliferation and/or differentiation factors functioning in hematopoietic systems and immune systems. Focusing their attention on the fact that most of the secretory proteins, such as proliferation and/or differentiation factors (for example, various cytokines etc.) and membrane proteins such as receptors thereof (hereafter these proteins will be referred to generally as secretory proteins and the like), have sequences called signal peptides in the N-termini, the inventors have conducted extensive studies on a process for efficiently and selectively cloning a gene encoding a signal peptide. Finally, we have successfully developed a method which can easily select a cDNA encoding a signal peptide (signal sequence trap (SST)) by using animal cells (See Japanese Published Patent Application No. Hei 6-315380). We also developed yeast SST method on the same conception. By the method based on the same conception using yeast (yeast SST method), genes encoding a signal peptide can be identified more easily and efficiently (See U.S. Pat. No. 5,536,637).

DISCLOSURE OF THE PRESENT INVENTION

[0005] The present inventors have diligently performed certain investigation in order to isolate novel factors (polypeptides) useful for treatment, diagnosis and/or study, particularly, secretory proteins containing a secretory signal and membrane proteins.

[0006] From the result, using the above methods, the present inventors achieved to find novel secretory proteins and membrane proteins produced from cell lines and tissue, for example, human adult brain tissue, cell lines derived from human brain tissue, cell lines derived from human bone marrow, and human fetal liver, and cDNAs encoding them, and then completed the present invention.

[0007] The present invention provides cDNA sequences identified as clones OM007 and OMB096 which were isolated by the above yeast SST method using cDNA libraries prepared from human adult brain tissue. Clones OM007 and OMB096 were full-length cDNAs including full cDNA sequences encoding secretory proteins (represented as OM007 and OMB096 proteins, respectively).

[0008] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequences of OM007 and OMB096 of the present invention and the nucleotide sequences encoding them. From these results, it was proved that the polypeptides of the present invention were new secretary proteins.

[0009] The present invention provides cDNA sequences identified as clones OAF0038-Leu and OAF038-Pro which were isolated by the above yeast SST method using cDNA libraries prepared from human adult born marrow (HAS303). Clones OAF0038-Leu and OAF038-Pro were full-length cDNAs including full cDNA sequences encoding membrane proteins (represented as OAF0038-Leu and OAF038-Pro proteins, respectively).

[0010] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequences of OAF0038-Leu and OFA038-Pro of the present invention and the nucleotide sequences encoding them. From these results, it was proved that the polypeptides of the present invention were new membrane proteins.

[0011] The present invention provides a cDNA sequence identified as clone OR087H which was isolated by the above yeast SST method using cDNA libraries prepared from human fetal liver. Clone OR087H was a full-length cDNA including a full cDNA sequence encoding a secretory protein (represented as OR087H protein).

[0012] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no-sequence identical to the polypeptide sequence of OR087H of the present invention and the nucleotide sequences encoding it. From these results, it was proved that the polypeptide of the present invention was a new secretary protein.

[0013] The present invention provides cDNA sequences identified as clones OA004-FG and OA004-LD which were isolated by the above yeast SST method using cDNA libraries prepared from a human glioblastoma cell line T98G. Clones OA004-FG and OA004-LD were full-length cDNAs including full cDNA sequences encoding membrane proteins (represented as OA004-FG and OA004-LD proteins, respectively).

[0014] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequences of OA004-FG and OA004-LD of the present invention and the nucleotide sequences encoding them. From these results, it was proved that polypeptides of the present invention were new membrane proteins.

[0015] That is to say, the present invention relates to:

[0016] (1) a polypeptide comprising the amino acid sequence of SEQ ID NOs: 1, 4, 7, 10, 13, 16 or 19,

[0017] (2) a cDNA encoding the polypeptide described in (1),

[0018] (3) a cDNA comprising the nucleotide sequence of SEQ ID NOs: 2, 5, 8, 11, 14, 17 or 20, and

[0019] (4) a cDNA comprising the nucleotide sequence of SEQ ID NOs: 3, 6, 9, 12, 15, 18 or 21.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

[0020] The present invention relates to a polypeptide in substantially purified form comprising the amino acid sequence shown in SEQ ID NOs: 1, 4, 7, 10, 13, 16 or 19, a homologue thereof, a fragment thereof, or a homologue of the fragment.

[0021] Further, the present invention relates to a cDNA encoding the above polypeptide. More particularly, the invention relates to a cDNA comprising the nucleotide sequence shown in SEQ ID NOs: 2, 5, 8, 11, 14, 17 or 20, and a cDNA containing a fragment which is selectively hybridized to a cDNA comprising the nucleotide sequence shown in SEQ ID NOs: 2, 3, 5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 20 or 21. The cDNA capable of hybridizing to the cDNA includes the contemporary sequence of the above sequence. The conditions of the hybridizing are preferably stringent.

[0022] The polypeptide in substantially purified form comprising the amino acid sequence shown in SEQ ID NOs: 1, 4, 7, 10, 13, 16 or 19 will generally comprise the polypeptide in a preparation in which 90% or more, e.g., 95%, 98% or 99%, of the polypeptide in the preparation is that of the SEQ ID NOs: 1, 4,7,10, 13, 16 or 19.

[0023] The homologue of the polypeptide comprising the amino acid sequence shown in SEQ ID NOs: 1, 4, 7, 10, 13, 16 or 19 will be generally at least 70%, preferably at least 80 or 90%, and more preferably at least 95%, homologous to the polypeptide over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 or more, contiguous amino acids. Such a polypeptide homologue will be referred to as “a polypeptide of the present invention”.

[0024] Also, the fragment of the polypeptide comprising the amino acid sequence shown in SEQ ID NOs: 1, 4, 7, 10, 13, 16 or 19 or its homologues will be generally at least 10, preferably at least 15, for example 20, 25, 30, 40, 50 or 60, amino acids in length.

[0025] The cDNA capable of selectively hybridizing to the cDNA comprising the nucleotide sequence shown in SEQ ID NOs: 2, 3, 5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 20 or 21 will be generally at least 70%, preferably at least 80 or 90%, and more preferably at least 95%, homologous to the cDNA over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 or more, contiguous nucleotides. Such a cDNA will be referred to as “a cDNA of the present invention”.

[0026] The fragment of the cDNA comprising the nucleotide sequence shown in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 20 or 21 will be at least 10, preferably at least 15, for example 20, 25, 30 or 40, nucleotides in length. Such a fragment will be also referred to as “a cDNA of the present invention”.

[0027] A further embodiment of the present invention provides replication and expression vectors carrying the cDNA of the present invention. The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the cDNA and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene. The vectors may be used in vitro, for example, in the production of RNA corresponding to the cDNA, or the transformation of a host cell.

[0028] A further embodiment of the present invention provides host cells transformed with the vectors for the replication and expression of the cDNA of the present invention, including the cDNA comprising the nucleotide sequence shown in SEQ ID NOs: 2, 3, 5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 20 or 21 or an open reading frame thereof. The cells include, for example, bacteria, yeast, insect cells, and mammalian cells.

[0029] A further embodiment of the present invention provides a method of producing a polypeptide which comprises culturing host cells of the present invention under conditions effective to express a polypeptide of the present invention. Preferably, in addition, such a method is carried out under conditions in which the polypeptide of the present invention is expressed and then produced from the host cells.

[0030] The cDNA of the present invention may also be inserted into the vectors described above in an antisense orientation in order to prove for the production of an antisense RNA. Such an antisense RNA may be used in a method of controlling the levels of the polypeptide of the present invention in a cell.

[0031] The present invention also provides monoclonal or polyclonal antibodies against the polypeptides of the present invention. The invention further provides a process for the production of monoclonal or polyclonal antibodies to the polypeptides of the present invention. The monoclonal antibodies may be prepared by common hybridoma technology using the polypeptides of the present invention or fragments thereof, as an immunogen. The polyclonal antibodies may also be prepared by common means which comprise inoculating host animals (for example, a rat, a rabbit, etc.) with the polypeptides of the present invention and recovering immune serum.

[0032] The present invention also provides pharmaceutical compositions comprising the polypeptide of the present invention or an antibody thereof, and a pharmaceutically acceptable diluent and/or carrier.

[0033] The polypeptides of the present invention specified in (1) include polypeptides in which a part of the amino acid sequence is lacking (e.g., a polypeptide comprised of only the essential sequence for revealing a biological activity from the amino acid sequence shown in SEQ ID NO: 1), polypeptides in which a part of their amino acid sequence is replaced by other amino acids (e.g., those replaced by an amino acid having a similar property), and polypeptides in which other amino acids are added or inserted into a part of their amino acid sequence, as well as those comprising the amino acid sequence shown in SEQ ID NOs: 1, 4, 7, 10,13, 16 or 19.

[0034] As is well-known, there are one to six codons that encodes one amino acid (for example, one kind of codon for Met, and six codons for Leu). Accordingly, the nucleotide sequence of cDNA can be changed in order to encode a polypeptide having the same amino acid sequence.

[0035] The cDNAs of the present invention specified in (2) include a group of every nucleotide sequence encoding the polypeptide (1) shown in SEQ ID NOs: 1, 4, 7, 10, 13, 16 or 19. There is a probability. that the yield of a polypeptide is improved by changing a nucleotide sequence.

[0036] The cDNAs specified by SEQ ID NOs: 2, 5, 8, 11, 14, 17 or 20 in (3) are the embodiment of the cDNAs shown in (2), and indicate the natural form of the sequence.

[0037] The cDNAs shown by SEQ ID NOs: 3, 6, 9, 12, 15, 18 or 21 in (4) indicates the sequence of the cDNAs specified in (3) with a natural non-translated region.

[0038] The cDNA having the nucleotide sequence shown in SEQ ID NOs: 3, 6, 9, 12, 15, 18, or 21 is prepared by the following method:

[0039] Brief description of Yeast SST method (see U.S. Pat. No. 5,536,637) is as follows.

[0040] Yeast, such as Saccharomyces cerevisiae, should secrete invertase into the medium in order to take sucrose or raffinose as a source of energy or carbon (the invertase is an enzyme to cleave raffinose into sucrose and melibiose, and sucrose into fructose and glucose). It is known that many known mammalian signal sequences make yeast secrete its invertase. From these knowledge, SST method was developed as a screening method to find a novel signal peptide which makes it possible to secrete yeast invertase from mammalian cDNA library using yeast growth on a raffinose medium as a marker.

[0041] Non-secretory type invertase gene SUC2 (GENBANK, Accession No. V01311) that lacks initiation codon ATG was inserted to a yeast expression vector to prepare vector pSUC2 for yeast SST. Into this expression vector, an expression promoter (ADH promoter) and a terminator (ADH terminator) both derived from AAH5 plasmid (Gammerer, Methods in Enzymol., 101, 192-201, 1983)) were inserted, and 2μ ori, TRP1, ColE1 ori and an ampicillin resistance gene were inserted as a yeast replication origin, a yeast selective marker, an E. coli replication origin and a drug resistance marker, respectively.

[0042] A mammalian cDNA was inserted into the upstream of SUC2 gene to prepare yeast SST cDNA library. This library was transformed into yeast that lacks secretory type invertase. If the inserted mammalian cDNA encodes a signal peptide, the yeast could survive in raffinose medium as a result of restoring secretion of invertase. Thus, it is possible to identify a novel signal peptide rapidly and easily by culturing expressed yeast colonies, preparing plasmids and determining the nucleotide sequence of the insert cDNAs,

[0043] Preparation of yeast SST cDNA library is as follows:

[0044] (1) mRNA is isolated from the targeted cells, double-strand synthesis is performed by using a random primer with a certain restriction enzyme (enzyme I) recognition site to obtain a double-strand cDNA,

[0045] (2) the obtained double-strand cDNA is ligated to an adapter containing a certain restriction endonuclease (enzyme II) recognition site, which is different from enzyme I, digested with enzyme I and fractionated to an appropriate size,

[0046] (3) the obtained cDNA fragment is inserted into a yeast expression vector on the upstream region of an invertase gene in which a signal peptide is deleted for transformation.

[0047] Detailed description of each step is as follows:

[0048] (1) mRNA is isolated from mammalian organs and cell lines stimulate them with an appropriate stimulator, if necessary) by known methods (Molecular Cloning (Sambrook, J., Fritsch, E. F. and Maniatis, T, Cold Spring Harbor Laboratory Press, 1989) or Current Protocol in Molecular Biology (F. M. Ausubel et al, John Wiley & Sons, Inc.) unless otherwise described hereinafter).

[0049] HAS303 (human bone marrow stroma cell line: provided from Professor Keisuke Sotoyama, Dr. Makoto Aizawa of First Medicine, Tokyo Medical College; see J. Cell. Physiol., 148, 245-251, 1991 and Experimental Hematol., 22, 482487, 1994), human glioblastoma cell line TG98G (ATCC No. CRL-1690), and human fetal liver (CLONTECH, #CL6527-1) are chosen as a cell line. Human adult brain is chosen as a tissue source. Double-strand cDNA synthesis using random primer is performed by known methods.

[0050] Any sites may be used as restriction endonuclease recognition site I which is linked to an adapter and restriction endonuclease recognition site II which is used in step (2) if both sites are different from each other. Preferably, XhoI is used as enzyme I and EcoRI as enzyme II.

[0051] In step (2), the cDNA is blunt-ended with T4 DNA polymerase, ligated to enzyme II adapter, digested with enzyme I, and fractionized to cDNAs of 300 to 800 bp with agarose-gel electrophoresis (AGE). As mentioned above, any enzyme may be used as enzyme II if it is different from enzyme I.

[0052] In step (3), cDNA fragments obtained in step (2) are inserted into a yeast expression plasmid vector on the upstream region of an invertase gene in which a signal peptide is deleted. E. coli was transformed with the expression vector. Many vectors are known as the yeast expression plasmid vector. For example, YEp24 which is also functioned in E. coli is used. Preferably, pSUC2 as described above is used.

[0053] Many host E. coli strains are known for transformation, preferably DH10B competent cell is used. Any known transformation method is available, preferably it is performed by electropolation method. The transformant is cultured by conventional methods to obtain cDNA library for yeast SST method.

[0054] However, the cDNA fragment is not inserted to all clones in this cDNA library. Further, all of the gene fragments do not encode unknown (novel) signal peptides. It is therefore necessary to screen a gene fragment encoding an unknown signal peptide from the library. Therefore, screening of fragments containing a sequence encoding a signal peptide is performed by transformation of the cDNA library into Saccharomyces cerevisiae having no invertase gene (e.g., YT455 strain) or a strain which artificially lacks an invertase gene (it may be prepared by known methods.).

[0055] Transformation of yeast is performed by known methods, e.g., lithium acetate method. A transformant is cultured in a selective medium, then transferred to a medium containing raffinose as a carbon source. Survival colonies are selected and then a plasmid is recovered. Survival colonies using raffinose as a carbon source indicates that some signal peptide of a secretory protein was inserted to this clone.

[0056] As for isolated positive clones, the nucleotide sequence is determined. As to a cDNA encoding an unknown protein, a full-length clone may be isolated by using the cDNA fragment as a probe and then the full-length nucleotide sequence was determined. These manipulations are performed by known methods.

[0057] Once the nucleotide sequences shown in SEQ ID NOs: 2, 5, 8, 11, 14, 17 or 20 are determined partially or preferably fully, it is possible to obtain cDNAs encoding the proteins of the present invention present in mammals or cDNAs encoding a homologue or subset of the proteins of the present invention. cDNA library or mRNA derived from mammals was screened by PCR with a synthesized oligonucleotide having an appropriate nucleotide sequence or by hybridization with a fragment having an appropriate nucleotide sequence as a probe. It is possible to obtain cDNAs encoding other mammalian homologue protein from other mammalian cDNA library or its genome library.

[0058] If the cDNA obtained above contains a nucleotide sequence of a cDNA fragment obtained by SST (or a consensus sequence thereof), it will be thought that the cDNA encodes the signal peptide. So it is clear that the cDNA will be full-length or almost full (all signal peptides exist at N-termini of a protein and are encoded at 5′-temini of the open reading frame of the cDNA).

[0059] The full-length may be confirmed by Northern analysis with the cDNA as a probe according to known methods. It is thought that the cDNA has an almost complete length, if the length of the cDNA is almost the same as the length of the mRNA obtained in the hybridizing band.

[0060] The proteins of the present invention include both a full-length type and a mature type. The full-length type and the mature type of the proteins are shown by SEQ ID NOs: 1, 4, 7, 10, 13, 16 and 19. These mature proteins can be obtained by expressing full-length cDNAs shown by SEQ ID NOs: 3, 6, 9, 12, 15, 18 and 21 in appropriate mammalian cells or other host cells. The sequence of the matured protein can be predicted from the amino acid sequence of the full-length type.

[0061] Once the nucleotide sequence shown in SEQ ID NOs: 2, 5, 8, 11, 14, 17 or 20 is determined, the cDNAs of the present invention can be obtained by chemical synthesis, or by hybridization making use of nucleotide fragments which have been chemically synthesized as a probe. Furthermore, the cDNAs of the present invention can be obtained in a desired amount by transforming a vector cDNA that contains the cDNA into a proper host, and culturing the transformant.

[0062] The polypeptides of the present invention may be prepared by, for example:

[0063] (1) isolating and purifying such polypeptides from an organism or a cultured cell,

[0064] (2) chemical peptide synthesis, or

[0065] (3) using recombinant cDNA technology, preferably, by the method described in (3) in an industrial production.

[0066] Examples of expression system (host-vector system) for producing a polypeptide by using recombinant cDNA technology are the expression systems of bacteria, yeast, insect cells and mammalian cells.

[0067] In the expression, for example, in E. coli, the expression vector is prepared by adding the initiation codon (ATG) to 5′-end of a cDNA encoding a mature protein, connecting the cDNA thus obtained to the downstream of a proper promoter (e.g., trp promoter, lac promoter, λPL promoter, T7 promoter etc.), and then inserting it into a vector (e.g., pBR322, pUC18, pUC19 etc.) which functions in an E. coli strain.

[0068] Then, an E. coli strain (e.g., E. coli DH1 strain, E. coli JM109 strain, E. coli HB101 strain, etc.) which is transformed with the expression vector described above may be cultured in an appropriate medium to obtain the desired polypeptide. When a signal sequence of bacteria (e.g., signal sequence of pel B) is utilized, the desired polypeptide may also be released in periplasm. Furthermore, a fusion protein with other polypeptide may also be produced.

[0069] In the expression of the polypeptides in mammalian cells, for example, the expression vector is prepared by inserting the cDNA encoding the nucleotide shown in SEQ ID NOs: 2, 5, 8, 11, 14, 17 or 20 into the downstream of a proper promoter (e.g., SV40 promoter, LTR promoter, metallothionein promoter, etc.) in a proper vector (e.g., retrovirus vector, papilloma virus vector, vaccinia virus vector, SV40 vector, etc.). A proper mammalian cell (e.g., monkey COS-7 cell, Chinese hamster CHO cell, mouse L cell, etc.) is transformed with the expression vector thus obtained, and then the transformant is cultured in a proper medium to express the protein (polypeptide) of the present invention by the following method depending on whether it is a secretory protein or a membrane protein.

[0070] In case of a secretory protein as the protein of the present invention, the aimed polypeptide was expressed in the supernatant of the cells. In addition, a fusion protein may be prepared by conjugating a cDNA fragment encoding other polypeptide, for example, the Fc portion of an antibody.

[0071] On the other hand, in case of a membrane protein as the protein of the present invention, the aimed polypeptide was expressed on the cell membrane. A cDNA encoding the nucleotide sequence of SEQ ID NO. 9, 12, 18 or 21 with deletion of the extracellular region was inserted into the above vector, transfected into the adequate mammalian cells to secret the aimed soluble polypeptide in the culture medium. In addition, a fusion protein may be prepared by conjugating a cDNA fragment encoding the mutant with deletion of the extracellular region and other polypeptide, for example, the Fc portion of an antibody.

[0072] The polypeptide available by the way described above can be isolated and purified by conventional biochemical method.

INDUSTRIAL APPLICABILITY

[0073] It is considered that the polypeptides of the present invention and cDNAs encoding them will show one or more effects or biological activities (including those which relates to assays cited below). The effects or biological activities described in relation to the proteins of the present invention are provided by administration or use of the protein or by administration or use of a cDNA molecule which encodes the protein (e.g., vector suitable for gene therapy or cDNA introduction).

[0074] Cytokine Activity and Cell Proliferation/Differentiation Activity:

[0075] The protein of the present invention may exhibit cytokine activity, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity, or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of the polypeptide of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines.

[0076] Immune Stimulating/Suppressing Activity:

[0077] The protein of the present invention may also exhibit immune stimulating or immune suppressing activity. The protein of the present invention may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral infection, such as HIV, as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using the protein of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, leshmania, malaria, and various fungal infections, such as candida. Of course, in this regard, the protein of the present invention may also be useful where a boost to the immune system generally would be indicated, i.e., in the treatment of a cancer.

[0078] The protein of the present invention may be useful in the treatment of allergic reactions and conditions, such as asthma or other respiratory problems. The protein of the present invention may also be useful in the treatment of the other conditions required to suppress the immuno system (for example, asthma or respiratory disease).

[0079] The protein of the present invention may also suppress chronic or acute inflammation, for example, that associated with infection, such as septic shock or systemic inflammatory response syndrome (SIRS), inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines, such as TNF or IL-I, wherein the effect was demonstrated by IL-11.

[0080] Hematopoiesis Regulating Activity:

[0081] The protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis. The biological activities are concerned with the following all or some example(s), e.g., in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemia or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells, such as granulocytes and monocytes/macrophages, (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders, such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in vitro or ex vivo (i.e., in conjunction with bone marrow transplantation) as normal cells or genetically manipulated for gene therapy.

[0082] The activity of the protein of the present invention may, among other means, be measured by the following methods:

[0083] Tissue Generation/Regeneration Activity:

[0084] The protein of the present invention may also have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair, and in the treatment of bums, incisions and ulcers.

[0085] The protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, may be applied to the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing the protein of the present invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

[0086] The protein of the present invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. The protein of the present invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

[0087] Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. The protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, may be applied to the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing the protein inducing a tendon/ligament-like tissue may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon Ligament cells or progenitors ex vivo for return in vitro (in vivo) to effect tissue repair. The compositions of the present invention may also be useful in the treatment of tendinitis, Carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and a sequestering agent which is well known in the art as well as a carrier.

[0088] The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue. i.e. for the treatment of central and peripheral nervous system diseases and neuropathies. as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, the protein of the present invention may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using the protein of the present invention.

[0089] It is expected that the protein of the present invention may also exhibit activity for generation of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the proliferation of cells comprising such tissues. A part of the desired effects may be by inhibition of fibrotic scarring to allow normal tissue to regenerate.

[0090] The protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

[0091] Activin/Inhibin Activity:

[0092] The protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, the protein of the present invention alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the present invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary (See U.S. Pat. No. 4,798,885). The protein of the present invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

[0093] Chemotactic/Chemokinetic Activity:

[0094] The protein of the present invention may have chemotactic or chemokinetic activity, e.g., functioning as a chemokine, for mammalian cells, including, for example, monocytes, neutrophils, T-cells, mast cells, eosinophils and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting site.

[0095] If a protein or peptide can stimulate, directly or indirectly, the directed orientation or movement of such cell population, it has chemotactic activity for a particular cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

[0096] Hemostatic and Thrombolytic Activity:

[0097] The protein of the present invention may also exhibit hemostatic or thrombolyic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. The protein of the present invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting from, for example, infarction, stroke, etc.

[0098] Receptor/Ligand Activity:

[0099] The protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including cellular adhesion molecules such as Selectins, Integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The protein of the present invention (including, without limitation, fragments of receptors and ligands) per se may be useful as inhibitors of receptor/ligand interactions.

[0100] Other Activity:

[0101] The protein (polypeptide) of the present invention may also exhibit one or more of the following additional activities or effects: inhibiting growth of or killing the infecting agents including bacteria, viruses, fungi and other parasites; suppressing or enhancing body characteristics including height, weight, hair color, eye color, skin, other tissue pigmentation, size of organs, for example, breast augmentation, diminution etc.; effecting elimination of dietary fat, protein, carbohydrate; effecting behavioral characteristics including appetite, libido, stress, cognition (including cognitive disorders), depression and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases.

[0102] The protein with above activities, is suspected to have following functions by itself or interaction with its ligands or receptors or association with other molecules. For example, proliferation or cell death of B cells, T cells and/or mast cells; specific induction by promotion of class switch of immunoglobulin genes; differentiation of B cells to antibody-forming cells; proliferation, differentiation, or cell death of precursors of granulocytes; proliferation, differentiation, or cell death of precursors of monocytes-macrophages; proliferation, of up regulation or cell death of neutrophils, monocytes-macrophages, eosinophils and/or basophils; proliferation, or cell death of precursors of megakaryocytes; proliferation, differentiation, or cell death of precursors of neutrophils; proliferation, differentiation, or cell death of precursors of T cells and B cells; promotion of production of erythrocytes; sustainment of proliferation of erythrocytes, neutrophils, eosinophils, basophils, monocytes-macrophages, mast cells, precursors of megakaryocyte; promotion of migration of neutrophils, monocytes-macrophages, B cells and/or T cells; proliferation or cell death of thymocytes; suppression of differentiation of adipocytes; proliferation or cell death of natural killer cells; proliferation or cell death of hematopoietic stem cells; suppression of proliferation of stem cells and each hematopoietic precursor cells; promotion of differentiation from mesenchymal stem cells to osteoblasts or chondrocytes, proliferation or cell death of mesenchymal stem cells, osteoblasts or chondrocytes and promotion of bone absorption by activation of osteoclasts and promotion of differentiation from monocytes to osteoclasts.

[0103] The polypeptide of the present invention is also suspected to function to nervous system, so expected to have functions below; differentiation to kinds of neurotransmitter-responsive neurons, survival or cell death of these cells; promotion of proliferation or cell death of glial cells; spread of neural dendrites; survival or cell death of gangriocytes; proliferation, promotion of differentiation, or cell death of astrocytes; proliferation, survival or cell death of peripheral neurons; proliferation or cell death of Schwann cells; proliferation, survival or cell death of motoneurons.

[0104] Furthermore, in the process of development of early embryonic, the polypeptide of the present invention is expected to promote or inhibit the organogenesis of epidermis, brain, backbone, and nervous system by induction of ectoderm, that of notochord connective tissues (bone, muscle, tendon), hemocytes, heart, kidney, and genital organs by induction of mesoderm, and that of digestive apparatus (stomach, intestine, liver, pancreas), respiratory apparatus (lung, trachea) by induction of endoderm. In adult, also, this polypeptide is thought to proliferate or inhibit the above organs.

[0105] Therefore, the polypeptide of the present invention itself is expected to be used as an agent for the prevention or treatment of disease of progression or suppression of immune, nervous, or bone metabolic function, hypoplasia or overgrowth of hematopoietic cells: for example, inflammatory disease (rheumatism, ulcerative colitis, etc.), decrease of hematopoietic stem cells after bone marrow transplantation, decrease of leukocytes, platelets, B-cells, or T-cells after radiation exposure or chemotherapeutic dosage against cancer or leukemia, anemia, infectious disease, cancer, leukemia, AIDS, bone metabolic disease (osteoporosis etc.), various degenerative disease (Alzheimer's disease, multiple sclerosis, etc.), or nervous lesion.

[0106] In addition, since the polypeptide of the present invention is thought to induce the differentiation or growth of organs derived from ectoderm, mesoderm, and endoderm, this polypeptide is expected to be an agent for tissue repair (epidermis, bone, muscle, tendon, heart, kidney, stomach, intestine, liver, pancreas, lung, trachea, etc.).

[0107] By using polyclonal or monoclonal antibodies against the polypeptide of the present invention, quantitation of the polypeptide in the body can be performed. It can be used in the study of relationship between this polypeptide and disease or diagnosis of disease, and so on. Polyclonal and monoclonal antibodies can be prepared using the polypeptide or its fragment as an antigen by conventional methods.

[0108] Identification, purification or molecular cloning of known or unknown proteins which bind the polypeptide of the present invention (preferably polypeptide of extracellular domain) can be performed using the polypeptide of the present invention by, for example, preparation of the affinity-column.

[0109] Identification of the downstream signal transmission molecules which interact with the polypeptide of the present invention in cytoplasma and molecular cloning of the gene can be performed by west-western method using the polypeptide of the present invention (preferably polypeptide of transmembrane region or intracellular domain), or by yeast two-hybrid system using the cDNA (preferably cDNA encoding the transmembrane region or cytoplasmic domain of the polypeptide).

[0110] Agonists/antagonists of this receptor polypeptide and inhibitors between receptor and signal transduction molecules can be screened using the polypeptide of the present invention.

[0111] The cDNAs of the present invention are useful not only the important and essential template for the production of the polypeptide of the present invention which is expected to be largely useful, but also be useful for diagnosis or therapy (for example, treatment of gene lacking, treatment to stop the expression of the polypeptide by antisense cDNA (mRNA)). Genomic cDNA may be isolated with the cDNA of the present invention, as a probe. In the same manner, a human gene encoding a related polypeptide which can be highly homologous to the cDNA of the present invention or gene encoding a polypeptide highly homologous to the polypeptide of the present invention and a gene of animals excluding mouse encoding a polypeptide which can be highly homologous to the polypeptide of the present invention, also may be isolated.

[0112] Application to Medicaments:

[0113] The polypeptide of the present invention or the antibody specific for the polypeptide of the present invention is administered systemically or topically and in general orally or parenterally, preferably parenterally, intravenously and intraventricularly, for preventing or treating the diseases.

[0114] The doses to be administered depend upon age, body weight, symptom, desired therapeutic effect, route of administration, and duration of the treatment etc. In human adults, one dose per person is generally between 100 μg and 100 mg, by oral administration, up to several times per day, and between 10 μg and 100 mg, by parental administration, up to several times per day.

[0115] As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

[0116] The compounds of the present invention may be administered as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parental administration.

[0117] Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules. Capsules include soft and hard capsules.

[0118] In such compositions, one or more of the active compound(s) may be admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate, etc.). The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g., lubricating agents (such as magnesium stearate etc.), disintegrating agents (such as cellulose calcium glycolate, etc.), stabilizing agents (such as human serum albumin, lactose etc.), and assisting agents for dissolving (such as arginine, asparaginic acid etc.).

[0119] The tablets or pills may, if desired, be coated with a film of gastric or enteric materials (such as sugar, gelatin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose phthalate, etc.), or be coated with at least two films. And then, coating may include containment within capsules of absorbable materials such as gelatin.

[0120] Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, syrups and elixirs. In such compositions, one or more of the active compound(s) may be contained in inert diluent(s) commonly used (purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents, suspending agents, etc.), sweetening agents, flavoring agents, perfuming agents, and preserving agents.

[0121] Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g., stabilizing agents (sodium sulfite etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid, etc.). For preparation of such spray compositions, for example, the method described in the U.S. Pat. Nos. 2,868,691 or 3,095,355 may be used.

[0122] Injections for parental administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. In such compositions, one or more active compound(s) is or are admixed with at least one inert aqueous diluent(s) (distilled water for injection, physiological salt solution, etc.) or inert non-aqueous diluents(s)(propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSOLBATE 80 (Trademark) etc.).

[0123] Injections may comprise additional compound other than inert diluents: e.g., preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent (such as human serum albumin, lactose, etc.), and assisting agents, such as assisting agents for dissolving (arginine, asparaginic acid, etc.).

BEST MODE CARRYING OUT THE INVENTION

[0124] The invention is illustrated by the following examples, but the invention is not limited thereto.

EXAMPLE 1 Clone OM007

[0125] Preparation of Poly(A)⁺RNA:

[0126] A total RNA was prepared from human adult brain tissue by TRIzol reagent (Trademark, marketed by GIBCO BRL Co.). Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit (Trade name, marketed by Pharmacia Co.).

[0127] Preparation of Yeast SST cDNA Library:

[0128] A double strand cDNA was synthesized by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning (Trade name, marketed by GIBCOBRL Co.) with above poly(A)⁺RNA as template and random 9mer as primer which was containing XhoI site:

[0129] 5′-CGATTGAATTCTAGACCTGCCTCGAGNNNNNNNNN-3 (SEQ ID NO: 22).

[0130] The cDNA was ligated with EcoRI adapter by DNA ligation kit ver. 2 (Trade name, marketed by Takara Shuzo Co.; this kit was used in all ligating steps hereinafter.) and digested by XhoI. The cDNAs were separated by agarose-gel electrophoresis. 300 to 800 bp cDNAs were isolated and were ligated to EcoRI/NotI site of pSUC2 (see U.S. Pat. No. 5,536,637). E. coli DH10B strains were transformed by pSUC2 with electropolation to obtain yeast SST cDNA library.

[0131] Screening by SST Method and Determination of Nucleotide Sequence of SST Positive Clone:

[0132] Plasmids of the cDNA library were prepared. Yeast YTK12 strains were transformed by the plasmids with lithium acetate method (Current Protocols In Molecular Biology, 13.7.1). The transformed yeast were plated on a triptphan-free medium (CMD-Trp medium) for selection. The plate was incubated for 48 hour at 30° C. Replica of the colony (transformant) which was obtained by Accutran Replica Plater (Trade name, marketed by Schleicher & Schuell) were placed onto YPR plate containing raffinose for a carbon source, and the plate was incubated for 14 days at 30° C. After 3 days, each colony appeared was streaked on YPR plate again. The plates were incubated for 48 hours at 30° C. Single colony was inoculated to YPD medium and was incubated for 48 hours at 30° C. Then plasmids were prepared. An insert cDNA was amplified by PCR with two kind primers which exist on the end side of the cloning site on pSUC2 (sense strand primers were biotinylated). Biotinylated single strand of cDNAs were purified with Dynabeads (Trade name, marketed by DYNAL Co.) and the nucleotide sequences were determined. Sequencing was performed by Dye Terminator Cycle Sequencing Ready Reaction with DNA Sequencing kit (Trade name, marketed by Applied Biosystems Inc.) and the sequence was determined by DNA sequencer 373 (Applied Biosystems Inc.) (all sequencing hereafter was carried out with this method.).

[0133] We tried to carry out cloning of full-length cDNA which was proved to be new one according to the homology search for the obtained nucleotide sequences and deduced amino acid sequences in data base. We also confirmed that each cDNA contains a signal peptide in view of function and structure, by comparison with a known signal peptide and the deduced amino acid sequence.

[0134] Cloning of a Full-Length cDNA and Determination of Nucleotide Sequence:

[0135] A full-length cDNA was cloned using Marathon cDNA Amplification Kit (Trade name, marketed by Clontech Co.) according to 3′ RACE (Rapid Amplification of cDNA End) method. A double strand cDNA was prepared from the origin of each clone, i.e., poly(A)⁺RNA in human adult brain tissue. 27mer primer OM007-F3:

[0136] 5′-AACTGCAGATCTTGGGACTCATCAGCC-3′ (SEQ ID NO: 23)

[0137] containing the deduced initiation ATG codon region based on the information of the nucleotide sequence obtained by SST, was prepared. PCR was performed with the primer and an adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 28mer primer OM007-F2:

[0138] 5′-AAGAGGACATTGTTTTCATCATGGATGC-3′ (SEQ ID NO: 24)

[0139] was prepared additionally at 3′-end of OM007-F1 primer and then nested PCR was performed. A cDNA which was amplified with clone OM007 specifically was separated with agarose-gel electrophoresis, ligated to pT7 Blue-2 T-Vector (Trade name, marketed by Novagen Co.) and transfected into E. coli DH5a to prepare a plasmid. First, nucleotide sequences of 5′-end were determined, and the existence of nucleotide sequence OM007 SST cDNA was confirmed. A nucleotide sequence of full-length OM007 SST cDNA was determined and then the cDNA sequence shown in SEQ ID NO: 3 was obtained. An open reading frame was determined and deduced an amino acid sequence, and sequences shown in SEQ ID NOs: 1 and 2 were obtained.

[0140] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence of OM007 of the present invention and the nucleotide sequences encoding them. From these results, it was proved that polypeptide of the present invention was a new secretary protein. However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM007 (region of 21st to 765th amino acid in SEQ ID NO: 1) and a region of 9th to 753rd amino acids chicken collapsin-2 (collapsin-2, (Gallus gallus), Genbank Accession U28240). Based on the homology, clone OM007 and semaphorin family to which collapsin belongs are expected to share at least some activity.

EXAMPLE 2 Clone OMB096

[0141] In Example relating to clone OMB096 of the present invention, the same procedure as in Example of OM007 was used, except for the following points.

[0142] Cloning of a Full-Length cDNA and Determination of Nucleotide Sequence:

[0143] A full-length cDNA was cloned using Marathon cDNA Amplification Kit (Trade name, marketed by Clontech Co.) according to 3′ RACE method in the same manner as in Example of OM007. A double strand cDNA was prepared from the origin of each clone, i.e., poly(A)⁺RNA in human adult brain tissue. 27mer primer OMB096-F1:

[0144] 5′-ACAACATGCACCACCAGTGGCTTCTGC-3′ (SEQ ID NO: 25)

[0145] containing the deduced initiation ATG codon region based on the information of the nucleotide sequence obtained by SST, was prepared. PCR was performed with the primer and an adapter primer attached in the kit. A cDNA which was amplified with clone OMB096 specifically was cloned in the same manner as in Example of OM007, a full nucleotide sequence was determined and then a cDNA sequence shown in SEQ ID NO: 6 was obtained. An open reading frame was determined and deduced an amino acid sequence, and sequences shown in SEQ ID NOs: 4 and 5 were obtained.

[0146] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence OMB096 of the present invention and the nucleotide sequences encoding it. From these results, it was proved that polypeptide of the present invention was a new secretary protein.

EXAMPLE 3

[0147] Clones OAF038-Leu and OAF038-Pro

[0148] In Example relating to clones OAF038-Leu and OAF038-Pro of the present invention, the same procedure as in Example of OM007 was used, except for the following points.

[0149] Preparation of Poly(A)⁺RNA:

[0150] A total RNA was prepared from human bone marrow stroma cell line HAS303 (provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent (Trademark, marketed by GIBCOBRL Co.). Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit (Trade name, marketed by Pharmacia Co.).

[0151] Cloning of a Full-Length cDNA and Determination of Nucleotide Sequence:

[0152] A full-length cDNA was cloned using Marathon cDNA Amplification Kit (Trade name, marketed by Clontech Co.) according to 3′ RACE method in the same manner as in Example of OM007. Double strand cDNA was prepared from the origin of each clone, i.e., poly(A)⁺RNA in HAS303. 28mer primer OAF038-F1:

[0153] 5′-AGAATGTGGAGCCATTTGAACAGGCTCC-3′ (SEQ ID NO. 26)

[0154] containing the deduced initiation ATG codon region based on the information of the nucleotide sequence obtained by SST, was prepared. PCR was performed with the primer and an adapter primer attached in the kit. A cDNA which was amplified with clone OAF038 specifically was separated with recloning by the same method as in Example of OM007, a full-length nucleotide sequence was determined, and then cDNA sequences shown in SEQ ID NOs: 9 and 12 were obtained. Each clone was named OAF038-Leu and OAF308-Pro, respectively. Open reading frames were determined and deduced amino acid sequences, and sequences shown in SEQ ID NOs: 7 and 8 and NOs: 10 and 11, respectively, were obtained.

[0155] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequences of OAF038-Leu and OAF038-Pro of the present invention and the nucleotide sequences encoding them. From these results, it was proved that polypeptides of the present invention were new membrane proteins. However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clones OAF038-Leu and OAF038-Pro (region of 5th to 343rd amino acids in SEQ ID NOs: 7 and 10) and rat MCA-32 protein (Rat MCA-32 protein, Genbank Accession U39546, a region of 42nd to 268th amino acids). Polypeptides OAF038-Leu and OAF038-Pro have Ig domain and SH2 domain at the extracell domain and the cytoplasmic domain, respectively, in the same manner as Rat MCA-32 protein. Based on the homology, clones OAF038-Leu and OAF038-Pro and the above Rat MCA-32 protein are expected to share at least some activity.

EXAMPLE 4 Clone OR087H

[0156] In Example relating to clone OR087H of the present invention, the same procedure as in Example of OM007 was used, except for the following points.

[0157] Preparation of Poly(A)⁺RNA:

[0158] We purchased poly(A)⁺RNA (CL6527-1) in human fetal liver from CLONTECH Co.

[0159] Cloning of a Full-Length cDNA and Determination of Nucleotide Sequence:

[0160] A full-length cDNA was cloned using Marathon cDNA Amplification Kit (Trade name, marketed by Clontech Co.) according to 3′ RACE method in the same manner as in Example of OM007. A double strand cDNA conjugating an adapter was prepared from the origin of each clone, i.e., poly(A)⁺RNA in human fetal liver according to the method of the kit. 27mer primer OR087H-F1:

[0161] 5′-TGAAGCCCTTGTCCGTAAGCCTTGAAC-3′ (SEQ ID NO: 27)

[0162] containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the primer and an adapter primer attached in the kit. A cDNA which was amplified with clone OR087H specifically was separated with recloning by the same method as in Example of OM007. A full-length nucleotide sequence was determined and then cDNA sequence shown in SEQ ID NO: 15 was obtained. An open reading frame was determined and deduced an amino acid sequence and sequences shown in SEQ ID NOs: 13 and 14 were obtained.

[0163] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence of OR087H of the present invention and the nucleotide sequences encoding them. From these results, it was proved that polypeptide of the present invention was a new secretary protein. However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OR087H (region of 1st to 115th amino acids in SEQ ID NO: 13) and human rapamycin- and FK506-binding protein (rapamycin- and FK506-binding protein (Homo sapiens), Genbank Accession M75099, a region of 1st to 116th amino acids). Based on the homology, clone OR087H and FK-binding protein family are expected to share at least some activity.

EXAMPLE 5 Clones OA004-FG and OA004-LD

[0164] In Example relating to clones OA004-FG and OA004-LD of the present invention, the same procedure as in Example of OM007 was used, except for the following points.

[0165] Preparation of Poly(A)⁺RNA:

[0166] Total RNA was prepared from human glioblastoma cell line T98G (ATCC No. CRL-1690) by TRIzol reagent (Trademark, marketed by GIBCOBRL Co.). Poly(A)⁺RNA was purified from the total RNA by mRNA Purification Kit (Trade name, marketed by Pharmacia Co.).

[0167] Cloning of a Full-Length cDNA and Determination of Nucleotide Sequence:

[0168] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System (Trade name, marketed by GIBCOBRL). First, dT-primed cDNA library was prepared from poly(A)⁺RNA in human glioblastoma cell line T98G using pSPORT1 plasmid (marketed by GIBCOBRL), as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning (Trade name, marketed by GIBCOBRL). Next, after preparing 27 mer biotinylated primer OA004-F1:

[0169]5′ biotin-ATGCACATCTTCAAGCATGCTCAG-3′ (SEQ ID NO: 28)

[0170] based on the information of the nucleotide sequence obtained by SST, plasmids hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. coli DH10B. Colony hybridization with OA004 SST cDNA which was labeled with ³²P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit (Trade name, marketed by Takara Shuzo Co.) according to a known method to isolate a positive clone and to prepare a plasmid. After the nucleotide sequence at the 5′-side was determined to confirm that the nucleotide sequence of OA004 SST cDNA was present, a full-length nucleotide sequence was determined, cDNA sequences shown in SEQ ID NOs: 18 and 21 were obtained and named OA004-FG and OA004-LD, respectively. Furthermore, open reading frames were determined and deduced amino acid sequences, and sequences shown in SEQ ID NOs: 16 and 17 and NOs: 19 and 20, respectively, were obtained.

[0171] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequences of OA004-FG and OA004-LD of the present invention and the nucleotide sequences encoding them. From these results, it was proved that polypeptides of the present invention were new secretary proteins. However, as a results of homology search, BLASTX, BLASTP and FASTA revealed a significant homology between clones OA004-FG and OA004-LD (region of 151st to 353rd amino acids in SEQ ID NOs: 16 and 19) and C. elegans 52.8 kD protein (Hypothetical 52.8 kD protein (Caenorhabdtis elegans), SwissProt Accession YJ95_CAEEL, region of 238th to 453rd amino acids). Moreover, they revealed a significant homology between clones OA004-FG and OA004-LD (region of 236th to 319th amino acids in SEQ ID NOs: 16 and 19) and human presenillin-2 (presenillin-2 (Homo sapiens), Genbank Accession A56993, region of 340th to 416th amino acids). Based on these homologies, clones OA004-FG and OA004-LD and presenillin family were expected to share at least some activity.

1 28 1 777 PRT Homo sapiens misc_feature Origin human brain-derived clone 0M007 1 Met Asn Ala Asn Lys Asp Glu Arg Leu Lys Ala Arg Ser Gln Asp Phe -35 -30 -25 His Leu Phe Pro Ala Leu Met Met Leu Ser Met Thr Met Leu Phe Leu -20 -15 -10 -5 Pro Val Thr Gly Thr Leu Lys Gln Asn Ile Pro Arg Leu Lys Leu Thr -1 1 5 10 Tyr Lys Asp Leu Leu Leu Ser Asn Ser Cys Ile Pro Phe Leu Gly Ser 15 20 25 Ser Glu Gly Leu Asp Phe Gln Thr Leu Leu Leu Asp Glu Glu Arg Gly 30 35 40 Arg Leu Leu Leu Gly Ala Lys Asp His Ile Phe Leu Leu Ser Leu Val 45 50 55 60 Asp Leu Asn Lys Asn Phe Lys Lys Ile Tyr Trp Pro Ala Ala Lys Glu 65 70 75 Arg Val Glu Leu Cys Lys Leu Ala Gly Lys Asp Ala Asn Thr Glu Cys 80 85 90 Ala Asn Phe Ile Arg Val Leu Gln Pro Tyr Asn Lys Thr His Ile Tyr 95 100 105 Val Cys Gly Thr Gly Ala Phe His Pro Ile Cys Gly Tyr Ile Asp Leu 110 115 120 Gly Val Tyr Lys Glu Asp Ile Ile Phe Lys Leu Asp Thr Arg Asn Leu 125 130 135 140 Glu Ser Gly Arg Leu Lys Cys Pro Phe Asp Pro Gln Gln Pro Phe Ala 145 150 155 Ser Val Met Thr Asp Glu Tyr Leu Tyr Ser Gly Thr Ala Ser Asp Phe 160 165 170 Leu Gly Lys Asp Thr Ala Phe Thr Arg Ser Leu Gly Pro Thr His Asp 175 180 185 His His Tyr Ile Arg Thr Asp Ile Ser Glu His Tyr Trp Leu Asn Gly 190 195 200 Ala Lys Phe Ile Gly Thr Phe Phe Ile Pro Asp Thr Tyr Asn Pro Asp 205 210 215 220 Asp Asp Lys Ile Tyr Phe Phe Phe Arg Glu Ser Ser Gln Glu Gly Ser 225 230 235 Thr Ser Asp Lys Thr Ile Leu Ser Arg Val Gly Arg Val Cys Lys Asn 240 245 250 Asp Val Gly Gly Gln Arg Ser Leu Ile Asn Lys Trp Thr Thr Phe Leu 255 260 265 Lys Ala Arg Leu Ile Cys Ser Ile Pro Gly Ser Asp Gly Ala Asp Thr 270 275 280 Tyr Phe Asp Glu Leu Gln Asp Ile Tyr Leu Leu Pro Thr Arg Asp Glu 285 290 295 300 Arg Asn Pro Val Val Tyr Gly Val Phe Thr Thr Thr Ser Ser Ile Phe 305 310 315 Lys Gly Ser Ala Val Cys Val Tyr Ser Met Ala Asp Ile Arg Ala Val 320 325 330 Phe Asn Gly Pro Tyr Ala His Lys Glu Ser Ala Asp His Arg Trp Val 335 340 345 Gln Tyr Asp Gly Arg Ile Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser 350 355 360 Lys Thr Tyr Asp Pro Leu Ile Lys Ser Thr Arg Asp Phe Pro Asp Asp 365 370 375 380 Val Ile Ser Phe Ile Lys Arg His Ser Val Met Tyr Lys Ser Val Tyr 385 390 395 Pro Val Ala Gly Gly Pro Thr Phe Lys Arg Ile Asn Val Asp Tyr Arg 400 405 410 Leu Thr Gln Ile Val Val Asp His Val Ile Ala Glu Asp Gly Gln Tyr 415 420 425 Asp Val Met Phe Leu Gly Thr Asp Ile Gly Thr Val Leu Lys Val Val 430 435 440 Ser Ile Ser Lys Glu Lys Trp Asn Met Glu Glu Val Val Leu Glu Glu 445 450 455 460 Leu Gln Ile Phe Lys His Ser Ser Ile Ile Leu Asn Met Glu Leu Ser 465 470 475 Leu Lys Gln Gln Gln Leu Tyr Ile Gly Ser Arg Asp Gly Leu Val Gln 480 485 490 Leu Ser Leu His Arg Cys Asp Thr Tyr Gly Lys Ala Cys Ala Asp Cys 495 500 505 Cys Leu Ala Arg Asp Pro Tyr Cys Ala Trp Asp Gly Asn Ala Cys Ser 510 515 520 Arg Tyr Ala Pro Thr Ser Lys Arg Arg Ala Arg Arg Gln Asp Val Lys 525 530 535 540 Tyr Gly Asp Pro Ile Thr Gln Cys Trp Asp Ile Glu Asp Ser Ile Ser 545 550 555 His Glu Thr Ala Asp Glu Lys Val Ile Phe Gly Ile Glu Phe Asn Ser 560 565 570 Thr Phe Leu Glu Cys Ile Pro Lys Ser Gln Gln Ala Thr Ile Lys Trp 575 580 585 Tyr Ile Gln Arg Ser Gly Asp Glu His Arg Glu Glu Leu Lys Pro Asp 590 595 600 Glu Arg Ile Ile Lys Thr Glu Tyr Gly Leu Leu Ile Arg Ser Leu Gln 605 610 615 620 Lys Lys Asp Ser Gly Met Tyr Tyr Cys Lys Ala Gln Glu His Thr Phe 625 630 635 Ile His Thr Ile Val Lys Leu Thr Leu Asn Val Ile Glu Asn Glu Gln 640 645 650 Met Glu Asn Thr Gln Arg Ala Glu His Glu Glu Gly Gln Val Lys Asp 655 660 665 Leu Leu Ala Glu Ser Arg Leu Arg Tyr Lys Asp Tyr Ile Gln Ile Leu 670 675 680 Ser Ser Pro Asn Phe Ser Leu Asp Gln Tyr Cys Glu Gln Met Trp His 685 690 695 700 Arg Glu Lys Arg Arg Gln Arg Asn Lys Gly Gly Pro Lys Trp Lys His 705 710 715 Met Gln Glu Met Lys Lys Lys Arg Asn Arg Arg His His Arg Asp Leu 720 725 730 Asp Glu Leu Pro Arg Ala Val Ala Thr 735 740 2 2331 DNA Homo sapiens 2 atgaatgcta ataaagatga aagacttaaa gccagaagcc aagattttca cctttttcct 60 gctttgatga tgctaagcat gaccatgttg tttcttccag tcactggcac tttgaagcaa 120 aatattccaa gactcaagct aacctacaaa gacttgctgc tttcaaatag ctgtattccc 180 tttttgggtt catcagaagg actggatttt caaactcttc tcttagatga ggaaagaggc 240 aggctgctct tgggagccaa agaccacatc tttctactca gtctggttga cttaaacaaa 300 aattttaaga agatttattg gcctgctgca aaggaacggg tggaattatg taaattagct 360 gggaaagatg ccaatacaga atgtgcaaat ttcatcagag tacttcagcc ctataacaaa 420 actcacatat atgtgtgtgg aactggagca tttcatccaa tatgtgggta tattgatctt 480 ggagtctaca aggaggatat tatattcaaa ctagacacac gtaatttgga gtctggcaga 540 ctgaaatgtc ctttcgatcc tcagcagcct tttgcttcag taatgacaga tgagtacctc 600 tactctggaa cagcttctga tttccttggc aaagatactg cattcactcg atcccttggg 660 cctactcatg accaccacta catcagaact gacatttcag agcactactg gctcaatgga 720 gcaaaattta ttggaacttt cttcatacca gacacctaca atccagatga tgataaaata 780 tatttcttct ttcgtgaatc atctcaagaa ggcagtacct ccgataaaac catcctttct 840 cgagttggaa gagtttgtaa gaatgatgta ggaggacaac gcagcctgat aaacaagtgg 900 acgacttttc ttaaggccag actgatttgc tcaattcctg gaagtgatgg ggcagatact 960 tactttgatg agcttcaaga tatttattta ctccccacaa gagatgaaag aaatcctgta 1020 gtatatggag tctttactac aaccagctcc atcttcaaag gctctgctgt ttgtgtgtat 1080 agcatggctg acatcagagc agtttttaat ggtccatatg ctcataagga aagtgcagac 1140 catcgttggg tgcagtatga tgggagaatt ccttatccac ggcctggtac atgtccaagc 1200 aaaacctatg acccactgat taagtccacc cgagattttc cagatgatgt catcagtttc 1260 ataaagcggc actctgtgat gtataagtcc gtatacccag ttgcaggagg accaacgttc 1320 aagagaatca atgtggatta cagactgaca cagatagtgg tggatcatgt cattgcagaa 1380 gatggccagt acgatgtaat gtttcttgga acagacattg gaactgtcct caaagttgtc 1440 agcatttcaa aggaaaagtg gaatatggaa gaggtagtgc tggaggagtt gcagatattc 1500 aagcactcat caatcatctt gaacatggaa ttgtctctga agcagcaaca attgtacatt 1560 ggttcccgag atggattagt tcagctctcc ttgcacagat gcgacactta tgggaaagct 1620 tgcgcagact gttgtcttgc cagagacccc tactgtgcct gggatggaaa tgcatgctct 1680 cgatatgctc ctacttctaa aaggagagct agacgccaag atgtaaaata tggcgaccca 1740 atcacccagt gctgggacat cgaagacagc attagtcatg aaactgctga tgaaaaggtg 1800 atttttggca ttgaatttaa ctcaaccttt ctggaatgta tacctaaatc ccaacaagca 1860 actattaaat ggtatatcca gaggtcaggg gatgagcatc gagaggagtt gaagcccgat 1920 gaaagaatca tcaaaacgga atatgggcta ctgattcgaa gtttgcagaa gaaggattct 1980 gggatgtatt actgcaaagc ccaggagcac actttcatcc acaccatagt gaagctgact 2040 ttgaatgtca ttgagaatga acagatggaa aatacccaga gggcagagca tgaggagggg 2100 caggtcaagg atctattggc tgagtcacgg ttgagataca aagactacat ccaaatcctt 2160 agcagcccaa acttcagcct cgaccagtac tgcgaacaga tgtggcacag ggagaagcgg 2220 agacagagaa acaagggggg cccaaagtgg aagcacatgc aggaaatgaa gaagaaacga 2280 aatcgaagac atcacagaga cctggatgag ctccctagag ctgtagccac g 2331 3 3880 DNA Homo sapiens misc_feature Origin human brain-derived clone 0M007 3 caccttacca actgcagatc ttgggactca tcagcctcaa taattatatt aaattaacac 60 catttgaaag agaacattgt tttcatc atg aat gct aat aaa gat gaa aga ctt 114 Met Asn Ala Asn Lys Asp Glu Arg Leu -35 -30 aaa gcc aga agc caa gat ttt cac ctt ttt cct gct ttg atg atg cta 162 Lys Ala Arg Ser Gln Asp Phe His Leu Phe Pro Ala Leu Met Met Leu -25 -20 -15 agc atg acc atg ttg ttt ctt cca gtc act ggc act ttg aag caa aat 210 Ser Met Thr Met Leu Phe Leu Pro Val Thr Gly Thr Leu Lys Gln Asn -10 -5 -1 1 5 att cca aga ctc aag cta acc tac aaa gac ttg ctg ctt tca aat agc 258 Ile Pro Arg Leu Lys Leu Thr Tyr Lys Asp Leu Leu Leu Ser Asn Ser 10 15 20 tgt att ccc ttt ttg ggt tca tca gaa gga ctg gat ttt caa act ctt 306 Cys Ile Pro Phe Leu Gly Ser Ser Glu Gly Leu Asp Phe Gln Thr Leu 25 30 35 ctc tta gat gag gaa aga ggc agg ctg ctc ttg gga gcc aaa gac cac 354 Leu Leu Asp Glu Glu Arg Gly Arg Leu Leu Leu Gly Ala Lys Asp His 40 45 50 atc ttt cta ctc agt ctg gtt gac tta aac aaa aat ttt aag aag att 402 Ile Phe Leu Leu Ser Leu Val Asp Leu Asn Lys Asn Phe Lys Lys Ile 55 60 65 tat tgg cct gct gca aag gaa cgg gtg gaa tta tgt aaa tta gct ggg 450 Tyr Trp Pro Ala Ala Lys Glu Arg Val Glu Leu Cys Lys Leu Ala Gly 70 75 80 85 aaa gat gcc aat aca gaa tgt gca aat ttc atc aga gta ctt cag ccc 498 Lys Asp Ala Asn Thr Glu Cys Ala Asn Phe Ile Arg Val Leu Gln Pro 90 95 100 tat aac aaa act cac ata tat gtg tgt gga act gga gca ttt cat cca 546 Tyr Asn Lys Thr His Ile Tyr Val Cys Gly Thr Gly Ala Phe His Pro 105 110 115 ata tgt ggg tat att gat ctt gga gtc tac aag gag gat att ata ttc 594 Ile Cys Gly Tyr Ile Asp Leu Gly Val Tyr Lys Glu Asp Ile Ile Phe 120 125 130 aaa cta gac aca cgt aat ttg gag tct ggc aga ctg aaa tgt cct ttc 642 Lys Leu Asp Thr Arg Asn Leu Glu Ser Gly Arg Leu Lys Cys Pro Phe 135 140 145 gat cct cag cag cct ttt gct tca gta atg aca gat gag tac ctc tac 690 Asp Pro Gln Gln Pro Phe Ala Ser Val Met Thr Asp Glu Tyr Leu Tyr 150 155 160 165 tct gga aca gct tct gat ttc ctt ggc aaa gat act gca ttc act cga 738 Ser Gly Thr Ala Ser Asp Phe Leu Gly Lys Asp Thr Ala Phe Thr Arg 170 175 180 tcc ctt ggg cct act cat gac cac cac tac atc aga act gac att tca 786 Ser Leu Gly Pro Thr His Asp His His Tyr Ile Arg Thr Asp Ile Ser 185 190 195 gag cac tac tgg ctc aat gga gca aaa ttt att gga act ttc ttc ata 834 Glu His Tyr Trp Leu Asn Gly Ala Lys Phe Ile Gly Thr Phe Phe Ile 200 205 210 cca gac acc tac aat cca gat gat gat aaa ata tat ttc ttc ttt cgt 882 Pro Asp Thr Tyr Asn Pro Asp Asp Asp Lys Ile Tyr Phe Phe Phe Arg 215 220 225 gaa tca tct caa gaa ggc agt acc tcc gat aaa acc atc ctt tct cga 930 Glu Ser Ser Gln Glu Gly Ser Thr Ser Asp Lys Thr Ile Leu Ser Arg 230 235 240 245 gtt gga aga gtt tgt aag aat gat gta gga gga caa cgc agc ctg ata 978 Val Gly Arg Val Cys Lys Asn Asp Val Gly Gly Gln Arg Ser Leu Ile 250 255 260 aac aag tgg acg act ttt ctt aag gcc aga ctg att tgc tca att cct 1026 Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile Cys Ser Ile Pro 265 270 275 gga agt gat ggg gca gat act tac ttt gat gag ctt caa gat att tat 1074 Gly Ser Asp Gly Ala Asp Thr Tyr Phe Asp Glu Leu Gln Asp Ile Tyr 280 285 290 tta ctc ccc aca aga gat gaa aga aat cct gta gta tat gga gtc ttt 1122 Leu Leu Pro Thr Arg Asp Glu Arg Asn Pro Val Val Tyr Gly Val Phe 295 300 305 act aca acc agc tcc atc ttc aaa ggc tct gct gtt tgt gtg tat agc 1170 Thr Thr Thr Ser Ser Ile Phe Lys Gly Ser Ala Val Cys Val Tyr Ser 310 315 320 325 atg gct gac atc aga gca gtt ttt aat ggt cca tat gct cat aag gaa 1218 Met Ala Asp Ile Arg Ala Val Phe Asn Gly Pro Tyr Ala His Lys Glu 330 335 340 agt gca gac cat cgt tgg gtg cag tat gat ggg aga att cct tat cca 1266 Ser Ala Asp His Arg Trp Val Gln Tyr Asp Gly Arg Ile Pro Tyr Pro 345 350 355 cgg cct ggt aca tgt cca agc aaa acc tat gac cca ctg att aag tcc 1314 Arg Pro Gly Thr Cys Pro Ser Lys Thr Tyr Asp Pro Leu Ile Lys Ser 360 365 370 acc cga gat ttt cca gat gat gtc atc agt ttc ata aag cgg cac tct 1362 Thr Arg Asp Phe Pro Asp Asp Val Ile Ser Phe Ile Lys Arg His Ser 375 380 385 gtg atg tat aag tcc gta tac cca gtt gca gga gga cca acg ttc aag 1410 Val Met Tyr Lys Ser Val Tyr Pro Val Ala Gly Gly Pro Thr Phe Lys 390 395 400 405 aga atc aat gtg gat tac aga ctg aca cag ata gtg gtg gat cat gtc 1458 Arg Ile Asn Val Asp Tyr Arg Leu Thr Gln Ile Val Val Asp His Val 410 415 420 att gca gaa gat ggc cag tac gat gta atg ttt ctt gga aca gac att 1506 Ile Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Leu Gly Thr Asp Ile 425 430 435 gga act gtc ctc aaa gtt gtc agc att tca aag gaa aag tgg aat atg 1554 Gly Thr Val Leu Lys Val Val Ser Ile Ser Lys Glu Lys Trp Asn Met 440 445 450 gaa gag gta gtg ctg gag gag ttg cag ata ttc aag cac tca tca atc 1602 Glu Glu Val Val Leu Glu Glu Leu Gln Ile Phe Lys His Ser Ser Ile 455 460 465 atc ttg aac atg gaa ttg tct ctg aag cag caa caa ttg tac att ggt 1650 Ile Leu Asn Met Glu Leu Ser Leu Lys Gln Gln Gln Leu Tyr Ile Gly 470 475 480 485 tcc cga gat gga tta gtt cag ctc tcc ttg cac aga tgc gac act tat 1698 Ser Arg Asp Gly Leu Val Gln Leu Ser Leu His Arg Cys Asp Thr Tyr 490 495 500 ggg aaa gct tgc gca gac tgt tgt ctt gcc aga gac ccc tac tgt gcc 1746 Gly Lys Ala Cys Ala Asp Cys Cys Leu Ala Arg Asp Pro Tyr Cys Ala 505 510 515 tgg gat gga aat gca tgc tct cga tat gct cct act tct aaa agg aga 1794 Trp Asp Gly Asn Ala Cys Ser Arg Tyr Ala Pro Thr Ser Lys Arg Arg 520 525 530 gct aga cgc caa gat gta aaa tat ggc gac cca atc acc cag tgc tgg 1842 Ala Arg Arg Gln Asp Val Lys Tyr Gly Asp Pro Ile Thr Gln Cys Trp 535 540 545 gac atc gaa gac agc att agt cat gaa act gct gat gaa aag gtg att 1890 Asp Ile Glu Asp Ser Ile Ser His Glu Thr Ala Asp Glu Lys Val Ile 550 555 560 565 ttt ggc att gaa ttt aac tca acc ttt ctg gaa tgt ata cct aaa tcc 1938 Phe Gly Ile Glu Phe Asn Ser Thr Phe Leu Glu Cys Ile Pro Lys Ser 570 575 580 caa caa gca act att aaa tgg tat atc cag agg tca ggg gat gag cat 1986 Gln Gln Ala Thr Ile Lys Trp Tyr Ile Gln Arg Ser Gly Asp Glu His 585 590 595 cga gag gag ttg aag ccc gat gaa aga atc atc aaa acg gaa tat ggg 2034 Arg Glu Glu Leu Lys Pro Asp Glu Arg Ile Ile Lys Thr Glu Tyr Gly 600 605 610 cta ctg att cga agt ttg cag aag aag gat tct ggg atg tat tac tgc 2082 Leu Leu Ile Arg Ser Leu Gln Lys Lys Asp Ser Gly Met Tyr Tyr Cys 615 620 625 aaa gcc cag gag cac act ttc atc cac acc ata gtg aag ctg act ttg 2130 Lys Ala Gln Glu His Thr Phe Ile His Thr Ile Val Lys Leu Thr Leu 630 635 640 645 aat gtc att gag aat gaa cag atg gaa aat acc cag agg gca gag cat 2178 Asn Val Ile Glu Asn Glu Gln Met Glu Asn Thr Gln Arg Ala Glu His 650 655 660 gag gag ggg cag gtc aag gat cta ttg gct gag tca cgg ttg aga tac 2226 Glu Glu Gly Gln Val Lys Asp Leu Leu Ala Glu Ser Arg Leu Arg Tyr 665 670 675 aaa gac tac atc caa atc ctt agc agc cca aac ttc agc ctc gac cag 2274 Lys Asp Tyr Ile Gln Ile Leu Ser Ser Pro Asn Phe Ser Leu Asp Gln 680 685 690 tac tgc gaa cag atg tgg cac agg gag aag cgg aga cag aga aac aag 2322 Tyr Cys Glu Gln Met Trp His Arg Glu Lys Arg Arg Gln Arg Asn Lys 695 700 705 ggg ggc cca aag tgg aag cac atg cag gaa atg aag aag aaa cga aat 2370 Gly Gly Pro Lys Trp Lys His Met Gln Glu Met Lys Lys Lys Arg Asn 710 715 720 725 cga aga cat cac aga gac ctg gat gag ctc cct aga gct gta gcc acg 2418 Arg Arg His His Arg Asp Leu Asp Glu Leu Pro Arg Ala Val Ala Thr 730 735 740 tagttttcta cttaatttaa agaaaagaat tccttaccta taaaaacatt gccttctgtt 2478 ttgtatatcc cttatagtaa ttcataaatg cttcccatgg agttttgcta aggcacaaga 2538 caataatctg aataagacaa tatgtgatga atataagaaa gggcaaaaaa ttcatttgaa 2598 ccagttttcc aagaacaaat cttgcacaag caaagtataa gaattatcct aaaaataggg 2658 ggtttacagt tgtaaatgtt ttatgttttg agttttggaa tttattgtca tgtaaatagt 2718 tgagctaagc aagccccgaa tttgatagtg tataaggtgc tttattccct cgaatgtcca 2778 ttaagcatgg aatttaccat gcagttgtgc tatgttctta tgaacagata tatcattcct 2838 attgagaacc agctaccttg tggtagggaa taagaggtca gacacaaatt aagacaactc 2898 ccattatcaa caggaacttt ctcagtgagc cattcactcc tggagaatgg tataggaatt 2958 tggagaggtg cattatttct ttctggccac tggggttaaa tttagtgtac tacaacattg 3018 atttactgaa gggcactaat gtttccccca ggatttctat tgactagtca ggagtaacag 3078 gttcacagag agaagttggt gcttagttat gtgtttttta gagtatatac taagctctac 3138 agggacagaa tgcttaataa atactttaat aagatatggg aaaatatttt aataaaacaa 3198 ggaaaacata atgatgtata atgcatcctg atgggaaggc atgcagatgg gatttgttag 3258 aagacagaag gaaagacagc cataaattct ggctttgggg aaaactcata tccccatgaa 3318 aaggaagaac aatcacaaat aaagtgagag taatgtaatg gagctctttt cactagggta 3378 taagtagctg ccaatttgta attcatctgt taaaaaaaat ctagattata acaaactgct 3438 agcaaaatct gaggaaacat aaattcttct gaagaatcat aggaagagta gacattttat 3498 ttataaccaa tgatatttca gtatatattt tctctctttt aaaaaatatt tatcatactc 3558 tgtatattat ttctttttac tgcctttatt ctctcctgta tattggattt tgtgattata 3618 tttgagtgaa taggagaaaa caatatataa cacacagaga attaagaaaa tgacatttct 3678 ggggagtggg gatatatatt tgttgaataa cagaacgagt gtaaaatttt aacaacggaa 3738 agggttaaat taactctttg acatcttcac tcaacctttt ctcattgctg agttaatctg 3798 ttgtaattgt agtattgttt ttgtaattta acaataaata agcctgctac atgtaaaaag 3858 aaccaaaaaa aaaaaaaaaa aa 3880 4 356 PRT Homo sapiens misc_feature Origin human brain-derived clone 0MB096 4 Met His His Gln Trp Leu Leu Leu Ala Ala Cys Phe Trp Val Ile Phe -15 -10 -5 Met Phe Met Val Ala Ser Lys Phe Ile Thr Leu Thr Phe Lys Asp Pro -1 1 5 10 15 Asp Val Tyr Ser Ala Lys Gln Glu Phe Leu Phe Leu Thr Thr Met Pro 20 25 30 Glu Val Arg Lys Leu Pro Glu Glu Lys His Ile Pro Glu Glu Leu Lys 35 40 45 Pro Thr Gly Lys Glu Leu Pro Asp Ser Gln Leu Val Gln Pro Leu Val 50 55 60 Tyr Met Glu Arg Leu Glu Leu Ile Arg Asn Val Cys Arg Asp Asp Ala 65 70 75 Leu Lys Asn Leu Ser His Thr Pro Val Ser Lys Phe Val Leu Asp Arg 80 85 90 95 Ile Phe Val Cys Asp Lys His Lys Ile Leu Phe Cys Gln Thr Pro Lys 100 105 110 Val Gly Asn Thr Gln Trp Lys Lys Val Leu Ile Val Leu Asn Gly Ala 115 120 125 Phe Ser Ser Ile Glu Glu Ile Pro Glu Asn Val Val His Asp His Glu 130 135 140 Lys Asn Gly Leu Pro Arg Leu Ser Ser Phe Ser Asp Ala Glu Ile Gln 145 150 155 Lys Arg Leu Lys Thr Tyr Phe Lys Phe Phe Ile Val Arg Asp Pro Phe 160 165 170 175 Glu Arg Leu Ile Ser Ala Phe Lys Asp Lys Phe Val His Asn Pro Arg 180 185 190 Phe Glu Pro Trp Tyr Arg His Glu Ile Ala Pro Gly Ile Ile Arg Lys 195 200 205 Tyr Arg Arg Asn Arg Thr Glu Thr Arg Gly Ile Gln Phe Glu Asp Phe 210 215 220 Val Arg Tyr Leu Gly Asp Pro Asn His Arg Trp Leu Asp Leu Gln Phe 225 230 235 Gly Asp His Ile Ile His Trp Val Thr Tyr Val Glu Leu Cys Ala Pro 240 245 250 255 Cys Glu Ile Met Tyr Ser Val Ile Gly His His Glu Thr Leu Glu Asp 260 265 270 Asp Ala Pro Tyr Ile Leu Lys Glu Ala Gly Ile Asp His Leu Val Ser 275 280 285 Tyr Pro Thr Ile Pro Pro Gly Ile Thr Val Tyr Asn Arg Thr Lys Val 290 295 300 Glu His Tyr Phe Leu Gly Ile Ser Lys Arg Asp Ile Arg Arg Leu Tyr 305 310 315 Ala Arg Phe Glu Gly Asp Phe Lys Leu Phe Gly Tyr Gln Lys Pro Asp 320 325 330 335 Phe Leu Leu Asn 5 1068 DNA Homo sapiens 5 atgcaccacc agtggcttct gctggccgca tgcttttggg tgattttcat gttcatggtg 60 gctagcaagt tcatcacgtt gacctttaaa gacccagatg tgtacagtgc caaacaggag 120 tttctgttcc tgacaaccat gccggaagtg aggaagttgc cagaagagaa gcacattcct 180 gaggaactga agccaactgg gaaggagctt ccagacagcc agctcgttca gcccctggtc 240 tacatggagc gcctggaact catcagaaac gtctgcaggg atgatgccct gaagaatctc 300 tcgcacactc ctgtctccaa gtttgtcctg gaccgaatat ttgtctgtga caagcacaag 360 attcttttct gccagactcc caaagtgggc aacacccagt ggaagaaagt gctgattgtt 420 ctaaatggag cattttcttc cattgaggag atccccgaaa acgtggtgca cgaccacgag 480 aagaacggcc ttcctcggct ctcttccttc agtgatgcag aaattcagaa gcgattgaaa 540 acatacttca agttttttat tgtaagagat cccttcgaaa gacttatttc tgcatttaag 600 gataaatttg ttcacaatcc ccggtttgag ccttggtaca ggcatgagat tgctcctggc 660 atcatcagaa aatacaggag gaaccggaca gagacccggg ggatccagtt tgaagatttc 720 gtgcgctacc tcggcgatcc gaaccacaga tggctagacc ttcagtttgg ggaccacatc 780 attcactggg tgacgtatgt agagctctgt gctccctgtg agataatgta cagtgtgatt 840 ggacaccacg agaccctgga ggacgatgcc ccatacatct taaaagaggc tggcattgac 900 cacctggtgt catacccgac tatccctccg ggcattaccg tgtataacag aaccaaggtg 960 gagcactatt tcctgggcat cagcaaacga gacatccgac gcctgtatgc ccgtttcgaa 1020 ggggacttta agctctttgg gtaccagaaa ccagactttt tgctaaac 1068 6 2479 DNA Homo sapiens misc_feature Origin human brain-derived clone 0MB096 6 acaac atg cac cac cag tgg ctt ctg ctg gcc gca tgc ttt tgg gtg att 50 Met His His Gln Trp Leu Leu Leu Ala Ala Cys Phe Trp Val Ile -15 -10 -5 ttc atg ttc atg gtg gct agc aag ttc atc acg ttg acc ttt aaa gac 98 Phe Met Phe Met Val Ala Ser Lys Phe Ile Thr Leu Thr Phe Lys Asp -1 1 5 10 cca gat gtg tac agt gcc aaa cag gag ttt ctg ttc ctg aca acc atg 146 Pro Asp Val Tyr Ser Ala Lys Gln Glu Phe Leu Phe Leu Thr Thr Met 15 20 25 30 ccg gaa gtg agg aag ttg cca gaa gag aag cac att cct gag gaa ctg 194 Pro Glu Val Arg Lys Leu Pro Glu Glu Lys His Ile Pro Glu Glu Leu 35 40 45 aag cca act ggg aag gag ctt cca gac agc cag ctc gtt cag ccc ctg 242 Lys Pro Thr Gly Lys Glu Leu Pro Asp Ser Gln Leu Val Gln Pro Leu 50 55 60 gtc tac atg gag cgc ctg gaa ctc atc aga aac gtc tgc agg gat gat 290 Val Tyr Met Glu Arg Leu Glu Leu Ile Arg Asn Val Cys Arg Asp Asp 65 70 75 gcc ctg aag aat ctc tcg cac act cct gtc tcc aag ttt gtc ctg gac 338 Ala Leu Lys Asn Leu Ser His Thr Pro Val Ser Lys Phe Val Leu Asp 80 85 90 cga ata ttt gtc tgt gac aag cac aag att ctt ttc tgc cag act ccc 386 Arg Ile Phe Val Cys Asp Lys His Lys Ile Leu Phe Cys Gln Thr Pro 95 100 105 110 aaa gtg ggc aac acc cag tgg aag aaa gtg ctg att gtt cta aat gga 434 Lys Val Gly Asn Thr Gln Trp Lys Lys Val Leu Ile Val Leu Asn Gly 115 120 125 gca ttt tct tcc att gag gag atc ccc gaa aac gtg gtg cac gac cac 482 Ala Phe Ser Ser Ile Glu Glu Ile Pro Glu Asn Val Val His Asp His 130 135 140 gag aag aac ggc ctt cct cgg ctc tct tcc ttc agt gat gca gaa att 530 Glu Lys Asn Gly Leu Pro Arg Leu Ser Ser Phe Ser Asp Ala Glu Ile 145 150 155 cag aag cga ttg aaa aca tac ttc aag ttt ttt att gta aga gat ccc 578 Gln Lys Arg Leu Lys Thr Tyr Phe Lys Phe Phe Ile Val Arg Asp Pro 160 165 170 ttc gaa aga ctt att tct gca ttt aag gat aaa ttt gtt cac aat ccc 626 Phe Glu Arg Leu Ile Ser Ala Phe Lys Asp Lys Phe Val His Asn Pro 175 180 185 190 cgg ttt gag cct tgg tac agg cat gag att gct cct ggc atc atc aga 674 Arg Phe Glu Pro Trp Tyr Arg His Glu Ile Ala Pro Gly Ile Ile Arg 195 200 205 aaa tac agg agg aac cgg aca gag acc cgg ggg atc cag ttt gaa gat 722 Lys Tyr Arg Arg Asn Arg Thr Glu Thr Arg Gly Ile Gln Phe Glu Asp 210 215 220 ttc gtg cgc tac ctc ggc gat ccg aac cac aga tgg cta gac ctt cag 770 Phe Val Arg Tyr Leu Gly Asp Pro Asn His Arg Trp Leu Asp Leu Gln 225 230 235 ttt ggg gac cac atc att cac tgg gtg acg tat gta gag ctc tgt gct 818 Phe Gly Asp His Ile Ile His Trp Val Thr Tyr Val Glu Leu Cys Ala 240 245 250 ccc tgt gag ata atg tac agt gtg att gga cac cac gag acc ctg gag 866 Pro Cys Glu Ile Met Tyr Ser Val Ile Gly His His Glu Thr Leu Glu 255 260 265 270 gac gat gcc cca tac atc tta aaa gag gct ggc att gac cac ctg gtg 914 Asp Asp Ala Pro Tyr Ile Leu Lys Glu Ala Gly Ile Asp His Leu Val 275 280 285 tca tac ccg act atc cct ccg ggc att acc gtg tat aac aga acc aag 962 Ser Tyr Pro Thr Ile Pro Pro Gly Ile Thr Val Tyr Asn Arg Thr Lys 290 295 300 gtg gag cac tat ttc ctg ggc atc agc aaa cga gac atc cga cgc ctg 1010 Val Glu His Tyr Phe Leu Gly Ile Ser Lys Arg Asp Ile Arg Arg Leu 305 310 315 tat gcc cgt ttc gaa ggg gac ttt aag ctc ttt ggg tac cag aaa cca 1058 Tyr Ala Arg Phe Glu Gly Asp Phe Lys Leu Phe Gly Tyr Gln Lys Pro 320 325 330 gac ttt ttg cta aac taatgcataa gacctatgaa ttcaaatatc tttattagac 1113 Asp Phe Leu Leu Asn 335 ctggggctaa ccaggtgaag atctgagccc agaaatgacc cttcctccac cacacccctc 1173 ctttgaggac gcccggggtc tcccacaggc ctgtgagttg cctcggcata tgacgcagaa 1233 ccccaactgt tacaacttag tttggatgta agatgctctg aggaccctgc ccacacccct 1293 gcgtgcatta ggatgtcgct ggcctttgct cacctcagag gggagaaaag gctaaagatt 1353 tgcagtttga cagcccagca gggaggaagc atcacacagc gttaggagcc gtttccttca 1413 ggtgttaagg aaggggatgc ccctgaggtt ctcctggcta gtcagggtgg cttcacccat 1473 cactggtggg ttgcaggaac agcacccagg actctgagga gggacagaga agcaaggggg 1533 ctgctgaaat cgcagagact tttgcagcat cagatctgag gagtaaaacg gcacctctgg 1593 ccttcatctt ggtgctgcga caattgtgga ggcaaagcat tctttctgtg actattttgt 1653 tcctgtagac agtcagcgat ggccagaggg tggtgtggtg tccaggggtc catctttcca 1713 gaatccatgc ctgtgtaatg ctggtccatg cttctgaacc tgtgtctgcc aagcgcctat 1773 ttcattcagc acaagacata cgattttaga aggtgagggg aggggaggct ttttctacct 1833 gagaagggga gtgtctttga gggccttaaa aggaccatgg cccaggaatg ggggcgctgg 1893 ttgggcttgg agctcaggct gctgtggatc ccggcgcatc agttctgact tgccttacct 1953 gggtggacag cagtgaatct ccacctgtct tctccaggga gctcccatgt tggggctgaa 2013 gacgagcagg ggcaacctgc cagcatcaca gaattcagtg tagtttatac atttcgattc 2073 ctttcatctc agcaaaatgg gcactgccag agccatttct gatcacacca ccatcctgga 2133 ccatgtgact ggaaggtggg taaccaagtt caccagcaat aaaacccagc gcccaggtag 2193 cctccagcag tgcggcttcc tggcaacaag gtaggccctg gtgcagggca agccgcagcg 2253 accatttcag ataccgtcca cagccaggac cgctgagaac tgggacagtt tcctgggatg 2313 agtgccagcc tgagcctgca tggtgccgcc gagcccgggg tggaggaggg agccaggctt 2373 cgcttcaagg cggcctctac cttttctcag aatggtttcc tgattgtgtc aatgtgaaag 2433 ttaaataaaa tttatgtgcc aaacctgaaa aaaaaaaaaa aaaaaa 2479 7 343 PRT Homo sapiens misc_feature Origin human bone marrow stroma cell HAS 303- derived clone 0AF038-Leu 7 Met Trp Ser His Leu Asn Arg Leu Leu Phe Trp Ser Ile Phe Ser Ser -15 -10 -5 Val Thr Cys Arg Lys Ala Val Leu Asp Cys Glu Ala Met Lys Thr Asn -1 1 5 10 Glu Phe Pro Ser Pro Cys Leu Asp Ser Lys Thr Lys Val Val Met Lys 15 20 25 Gly Gln Asn Val Ser Met Phe Cys Ser His Lys Asn Lys Ser Leu Gln 30 35 40 45 Ile Thr Tyr Ser Leu Phe Arg Arg Lys Thr His Leu Gly Thr Gln Asp 50 55 60 Gly Lys Gly Glu Pro Ala Ile Phe Asn Leu Ser Ile Thr Glu Ala His 65 70 75 Glu Ser Gly Pro Tyr Lys Cys Lys Ala Gln Val Thr Ser Cys Ser Lys 80 85 90 Tyr Ser Arg Asp Phe Ser Phe Thr Ile Val Asp Pro Val Thr Ser Pro 95 100 105 Val Leu Asn Ile Met Val Ile Gln Thr Glu Thr Asp Arg His Ile Thr 110 115 120 125 Leu His Cys Leu Ser Val Asn Gly Ser Leu Pro Ile Asn Tyr Thr Phe 130 135 140 Phe Glu Asn His Val Ala Ile Ser Pro Ala Ile Ser Lys Tyr Asp Arg 145 150 155 Glu Pro Ala Glu Phe Asn Leu Thr Lys Lys Asn Pro Gly Glu Glu Glu 160 165 170 Glu Tyr Arg Cys Glu Ala Lys Asn Arg Leu Pro Asn Tyr Ala Thr Tyr 175 180 185 Ser His Pro Val Thr Met Pro Ser Thr Gly Gly Asp Ser Cys Pro Phe 190 195 200 205 Cys Leu Lys Leu Leu Leu Pro Gly Leu Leu Leu Leu Leu Val Val Ile 210 215 220 Ile Leu Ile Leu Ala Phe Trp Val Leu Pro Lys Tyr Lys Thr Arg Lys 225 230 235 Ala Met Arg Asn Asn Val Pro Arg Asp Arg Gly Asp Thr Ala Met Glu 240 245 250 Val Gly Ile Tyr Ala Asn Ile Leu Glu Lys Gln Ala Lys Glu Glu Ser 255 260 265 Val Pro Glu Val Gly Ser Arg Pro Cys Val Ser Thr Ala Gln Asp Glu 270 275 280 285 Ala Lys His Ser Gln Glu Leu Gln Tyr Ala Thr Pro Val Phe Gln Glu 290 295 300 Val Ala Pro Arg Glu Gln Glu Ala Cys Asp Ser Tyr Lys Ser Gly Tyr 305 310 315 Val Tyr Ser Glu Leu Asn Phe 320 8 1029 DNA Homo sapiens 8 atgtggagcc atttgaacag gctcctcttc tggagcatat tttcttctgt cacttgtaga 60 aaagctgtat tggattgtga ggcaatgaaa acaaatgaat tcccttctcc atgtttggac 120 tcaaagacta aggtggttat gaagggtcaa aatgtatcta tgttttgttc ccataagaac 180 aaatcactgc agatcaccta ttcattgttt cgacgtaaga cacacctggg aacccaggat 240 ggaaaaggtg aacctgcgat ttttaaccta agcatcacag aagcccatga atcaggcccc 300 tacaaatgca aagcccaagt taccagctgt tcaaaataca gtcgtgactt cagcttcacg 360 attgtcgacc cggtgacttc cccagtgctg aacattatgg tcattcaaac agaaacagac 420 cgacatataa cattacattg cctctcagtc aatggctcgc tgcccatcaa ttacactttc 480 tttgaaaacc atgttgccat atcaccagct atttccaagt atgacaggga gcctgctgaa 540 tttaacttaa ccaagaagaa tcctggagaa gaggaagagt ataggtgtga agctaaaaac 600 agattgccta actatgcaac atacagtcac cctgtcacca tgccctcaac aggcggagac 660 agctgtcctt tctgtctgaa gctactactt ccagggttat tactgttgct ggtggtgata 720 atcctaattc tggctttttg ggtactgccc aaatacaaaa caagaaaagc tatgagaaat 780 aatgtgccca gggaccgtgg agacacagcc atggaagttg gaatctatgc aaatatcctt 840 gaaaaacaag caaaggagga atctgtgcca gaagtgggat ccaggccgtg tgtttccaca 900 gcccaagatg aggccaaaca ctcccaggag ctacagtatg ccacccccgt gttccaggag 960 gtggcaccaa gagagcaaga agcctgtgat tcttataaat ctggatatgt ctattctgaa 1020 ctcaacttc 1029 9 1370 DNA Homo sapiens misc_feature Origin human bone marrow stroma cell HAS 303- derived clone 0AF038-Leu 9 gggaga atg tgg agc cat ttg aac agg ctc ctc ttc tgg agc ata ttt 48 Met Trp Ser His Leu Asn Arg Leu Leu Phe Trp Ser Ile Phe -15 -10 tct tct gtc act tgt aga aaa gct gta ttg gat tgt gag gca atg aaa 96 Ser Ser Val Thr Cys Arg Lys Ala Val Leu Asp Cys Glu Ala Met Lys -5 -1 1 5 10 aca aat gaa ttc cct tct cca tgt ttg gac tca aag act aag gtg gtt 144 Thr Asn Glu Phe Pro Ser Pro Cys Leu Asp Ser Lys Thr Lys Val Val 15 20 25 atg aag ggt caa aat gta tct atg ttt tgt tcc cat aag aac aaa tca 192 Met Lys Gly Gln Asn Val Ser Met Phe Cys Ser His Lys Asn Lys Ser 30 35 40 ctg cag atc acc tat tca ttg ttt cga cgt aag aca cac ctg gga acc 240 Leu Gln Ile Thr Tyr Ser Leu Phe Arg Arg Lys Thr His Leu Gly Thr 45 50 55 cag gat gga aaa ggt gaa cct gcg att ttt aac cta agc atc aca gaa 288 Gln Asp Gly Lys Gly Glu Pro Ala Ile Phe Asn Leu Ser Ile Thr Glu 60 65 70 75 gcc cat gaa tca ggc ccc tac aaa tgc aaa gcc caa gtt acc agc tgt 336 Ala His Glu Ser Gly Pro Tyr Lys Cys Lys Ala Gln Val Thr Ser Cys 80 85 90 tca aaa tac agt cgt gac ttc agc ttc acg att gtc gac ccg gtg act 384 Ser Lys Tyr Ser Arg Asp Phe Ser Phe Thr Ile Val Asp Pro Val Thr 95 100 105 tcc cca gtg ctg aac att atg gtc att caa aca gaa aca gac cga cat 432 Ser Pro Val Leu Asn Ile Met Val Ile Gln Thr Glu Thr Asp Arg His 110 115 120 ata aca tta cat tgc ctc tca gtc aat ggc tcg ctg ccc atc aat tac 480 Ile Thr Leu His Cys Leu Ser Val Asn Gly Ser Leu Pro Ile Asn Tyr 125 130 135 act ttc ttt gaa aac cat gtt gcc ata tca cca gct att tcc aag tat 528 Thr Phe Phe Glu Asn His Val Ala Ile Ser Pro Ala Ile Ser Lys Tyr 140 145 150 155 gac agg gag cct gct gaa ttt aac tta acc aag aag aat cct gga gaa 576 Asp Arg Glu Pro Ala Glu Phe Asn Leu Thr Lys Lys Asn Pro Gly Glu 160 165 170 gag gaa gag tat agg tgt gaa gct aaa aac aga ttg cct aac tat gca 624 Glu Glu Glu Tyr Arg Cys Glu Ala Lys Asn Arg Leu Pro Asn Tyr Ala 175 180 185 aca tac agt cac cct gtc acc atg ccc tca aca ggc gga gac agc tgt 672 Thr Tyr Ser His Pro Val Thr Met Pro Ser Thr Gly Gly Asp Ser Cys 190 195 200 cct ttc tgt ctg aag cta cta ctt cca ggg tta tta ctg ttg ctg gtg 720 Pro Phe Cys Leu Lys Leu Leu Leu Pro Gly Leu Leu Leu Leu Leu Val 205 210 215 gtg ata atc cta att ctg gct ttt tgg gta ctg ccc aaa tac aaa aca 768 Val Ile Ile Leu Ile Leu Ala Phe Trp Val Leu Pro Lys Tyr Lys Thr 220 225 230 235 aga aaa gct atg aga aat aat gtg ccc agg gac cgt gga gac aca gcc 816 Arg Lys Ala Met Arg Asn Asn Val Pro Arg Asp Arg Gly Asp Thr Ala 240 245 250 atg gaa gtt gga atc tat gca aat atc ctt gaa aaa caa gca aag gag 864 Met Glu Val Gly Ile Tyr Ala Asn Ile Leu Glu Lys Gln Ala Lys Glu 255 260 265 gaa tct gtg cca gaa gtg gga tcc agg ccg tgt gtt tcc aca gcc caa 912 Glu Ser Val Pro Glu Val Gly Ser Arg Pro Cys Val Ser Thr Ala Gln 270 275 280 gat gag gcc aaa cac tcc cag gag cta cag tat gcc acc ccc gtg ttc 960 Asp Glu Ala Lys His Ser Gln Glu Leu Gln Tyr Ala Thr Pro Val Phe 285 290 295 cag gag gtg gca cca aga gag caa gaa gcc tgt gat tct tat aaa tct 1008 Gln Glu Val Ala Pro Arg Glu Gln Glu Ala Cys Asp Ser Tyr Lys Ser 300 305 310 315 gga tat gtc tat tct gaa ctc aac ttc tgaaatttac agaaacaaac 1055 Gly Tyr Val Tyr Ser Glu Leu Asn Phe 320 tacatctcag ggtaaggatg ctttttatga agctgatttc catgaacaaa aagcaaactt 1115 gaggctgagg cgggtggatc acagggtcag gagatcaaga ccatcctggc taacacgatg 1175 aaaccccgtc tctactaaaa aatacaaaaa ttagccaggt gtggtggtgt gtgtgtgtag 1235 tcccagctac tcgggaggct gaggcaggag aatcgcttga gcccgggagg cagaggttgc 1295 agtgagccaa gatcgtgcca ctgcactaca gcctgggcga caagagcaag acttcatctc 1355 aaaaaaaaaa aaaaa 1370 10 343 PRT Homo sapiens misc_feature Origin human bone marrow stroma cell HAS 303- derived clone 0AF038-Pro 10 Met Trp Ser His Leu Asn Arg Leu Leu Phe Trp Ser Ile Phe Ser Ser -15 -10 -5 Val Thr Cys Arg Lys Ala Val Leu Asp Cys Glu Ala Met Lys Thr Asn -1 1 5 10 Glu Phe Pro Ser Pro Cys Leu Asp Ser Lys Thr Lys Val Val Met Lys 15 20 25 Gly Gln Asn Val Ser Met Phe Cys Ser His Lys Asn Lys Ser Leu Gln 30 35 40 45 Ile Thr Tyr Ser Leu Phe Arg Arg Lys Thr His Pro Gly Thr Gln Asp 50 55 60 Gly Lys Gly Glu Pro Ala Ile Phe Asn Leu Ser Ile Thr Glu Ala His 65 70 75 Glu Ser Gly Pro Tyr Lys Cys Lys Ala Gln Val Thr Ser Cys Ser Lys 80 85 90 Tyr Ser Arg Asp Phe Ser Phe Thr Ile Val Asp Pro Val Thr Ser Pro 95 100 105 Val Leu Asn Ile Met Val Ile Gln Thr Glu Thr Asp Arg His Ile Thr 110 115 120 125 Leu His Cys Leu Ser Val Asn Gly Ser Leu Pro Ile Asn Tyr Thr Phe 130 135 140 Phe Glu Asn His Val Ala Ile Ser Pro Ala Ile Ser Lys Tyr Asp Arg 145 150 155 Glu Pro Ala Glu Phe Asn Leu Thr Lys Lys Asn Pro Gly Glu Glu Glu 160 165 170 Glu Tyr Arg Cys Glu Ala Lys Asn Arg Leu Pro Asn Tyr Ala Thr Tyr 175 180 185 Ser His Pro Val Thr Met Pro Ser Thr Gly Gly Asp Ser Cys Pro Phe 190 195 200 205 Cys Leu Lys Leu Leu Leu Pro Gly Leu Leu Leu Leu Leu Val Val Ile 210 215 220 Ile Leu Ile Leu Ala Phe Trp Val Leu Pro Lys Tyr Lys Thr Arg Lys 225 230 235 Ala Met Arg Asn Asn Val Pro Arg Asp Arg Gly Asp Thr Ala Met Glu 240 245 250 Val Gly Ile Tyr Ala Asn Ile Leu Glu Lys Gln Ala Lys Glu Glu Ser 255 260 265 Val Pro Glu Val Gly Ser Arg Pro Cys Val Ser Thr Ala Gln Asp Glu 270 275 280 285 Ala Lys His Ser Gln Glu Leu Gln Tyr Ala Thr Pro Val Phe Gln Glu 290 295 300 Val Ala Pro Arg Glu Gln Glu Ala Cys Asp Ser Tyr Lys Ser Gly Tyr 305 310 315 Val Tyr Ser Glu Leu Asn Phe 320 11 1029 DNA Homo sapiens 11 atgtggagcc atttgaacag gctcctcttc tggagcatat tttcttctgt cacttgtaga 60 aaagctgtat tggattgtga ggcaatgaaa acaaatgaat tcccttctcc atgtttggac 120 tcaaagacta aggtggttat gaagggtcaa aatgtatcta tgttttgttc ccataagaac 180 aaatcactgc agatcaccta ttcattgttt cgacgtaaga cacacccggg aacccaggat 240 ggaaaaggtg aacctgcgat ttttaaccta agcatcacag aagcccatga atcaggcccc 300 tacaaatgca aagcccaagt taccagctgt tcaaaataca gtcgtgactt cagcttcacg 360 attgtcgacc cggtgacttc cccagtgctg aacattatgg tcattcaaac agaaacagac 420 cgacatataa cattacattg cctctcagtc aatggctcgc tgcccatcaa ttacactttc 480 tttgaaaacc atgttgccat atcaccagct atttccaagt atgacaggga gcctgctgaa 540 tttaacttaa ccaagaagaa tcctggagaa gaggaagagt ataggtgtga agctaaaaac 600 agattgccta actatgcaac atacagtcac cctgtcacca tgccctcaac aggcggagac 660 agctgtcctt tctgtctgaa gctactactt ccagggttat tactgttgct ggtggtgata 720 atcctaattc tggctttttg ggtactgccc aaatacaaaa caagaaaagc tatgagaaat 780 aatgtgccca gggaccgtgg agacacagcc atggaagttg gaatctatgc aaatatcctt 840 gaaaaacaag caaaggagga atctgtgcca gaagtgggat ccaggccgtg tgtttccaca 900 gcccaagatg aggccaaaca ctcccaggag ctacagtatg ccacccccgt gttccaggag 960 gtggcaccaa gagagcaaga agcctgtgat tcttataaat ctggatatgt ctattctgaa 1020 ctcaacttc 1029 12 1370 DNA Homo sapiens misc_feature Origin human bone marrow stroma cell HAS 303- derived clone 0AF038-Pro 12 gggaga atg tgg agc cat ttg aac agg ctc ctc ttc tgg agc ata ttt 48 Met Trp Ser His Leu Asn Arg Leu Leu Phe Trp Ser Ile Phe -15 -10 tct tct gtc act tgt aga aaa gct gta ttg gat tgt gag gca atg aaa 96 Ser Ser Val Thr Cys Arg Lys Ala Val Leu Asp Cys Glu Ala Met Lys -5 -1 1 5 10 aca aat gaa ttc cct tct cca tgt ttg gac tca aag act aag gtg gtt 144 Thr Asn Glu Phe Pro Ser Pro Cys Leu Asp Ser Lys Thr Lys Val Val 15 20 25 atg aag ggt caa aat gta tct atg ttt tgt tcc cat aag aac aaa tca 192 Met Lys Gly Gln Asn Val Ser Met Phe Cys Ser His Lys Asn Lys Ser 30 35 40 ctg cag atc acc tat tca ttg ttt cga cgt aag aca cac ccg gga acc 240 Leu Gln Ile Thr Tyr Ser Leu Phe Arg Arg Lys Thr His Pro Gly Thr 45 50 55 cag gat gga aaa ggt gaa cct gcg att ttt aac cta agc atc aca gaa 288 Gln Asp Gly Lys Gly Glu Pro Ala Ile Phe Asn Leu Ser Ile Thr Glu 60 65 70 75 gcc cat gaa tca ggc ccc tac aaa tgc aaa gcc caa gtt acc agc tgt 336 Ala His Glu Ser Gly Pro Tyr Lys Cys Lys Ala Gln Val Thr Ser Cys 80 85 90 tca aaa tac agt cgt gac ttc agc ttc acg att gtc gac ccg gtg act 384 Ser Lys Tyr Ser Arg Asp Phe Ser Phe Thr Ile Val Asp Pro Val Thr 95 100 105 tcc cca gtg ctg aac att atg gtc att caa aca gaa aca gac cga cat 432 Ser Pro Val Leu Asn Ile Met Val Ile Gln Thr Glu Thr Asp Arg His 110 115 120 ata aca tta cat tgc ctc tca gtc aat ggc tcg ctg ccc atc aat tac 480 Ile Thr Leu His Cys Leu Ser Val Asn Gly Ser Leu Pro Ile Asn Tyr 125 130 135 act ttc ttt gaa aac cat gtt gcc ata tca cca gct att tcc aag tat 528 Thr Phe Phe Glu Asn His Val Ala Ile Ser Pro Ala Ile Ser Lys Tyr 140 145 150 155 gac agg gag cct gct gaa ttt aac tta acc aag aag aat cct gga gaa 576 Asp Arg Glu Pro Ala Glu Phe Asn Leu Thr Lys Lys Asn Pro Gly Glu 160 165 170 gag gaa gag tat agg tgt gaa gct aaa aac aga ttg cct aac tat gca 624 Glu Glu Glu Tyr Arg Cys Glu Ala Lys Asn Arg Leu Pro Asn Tyr Ala 175 180 185 aca tac agt cac cct gtc acc atg ccc tca aca ggc gga gac agc tgt 672 Thr Tyr Ser His Pro Val Thr Met Pro Ser Thr Gly Gly Asp Ser Cys 190 195 200 cct ttc tgt ctg aag cta cta ctt cca ggg tta tta ctg ttg ctg gtg 720 Pro Phe Cys Leu Lys Leu Leu Leu Pro Gly Leu Leu Leu Leu Leu Val 205 210 215 gtg ata atc cta att ctg gct ttt tgg gta ctg ccc aaa tac aaa aca 768 Val Ile Ile Leu Ile Leu Ala Phe Trp Val Leu Pro Lys Tyr Lys Thr 220 225 230 235 aga aaa gct atg aga aat aat gtg ccc agg gac cgt gga gac aca gcc 816 Arg Lys Ala Met Arg Asn Asn Val Pro Arg Asp Arg Gly Asp Thr Ala 240 245 250 atg gaa gtt gga atc tat gca aat atc ctt gaa aaa caa gca aag gag 864 Met Glu Val Gly Ile Tyr Ala Asn Ile Leu Glu Lys Gln Ala Lys Glu 255 260 265 gaa tct gtg cca gaa gtg gga tcc agg ccg tgt gtt tcc aca gcc caa 912 Glu Ser Val Pro Glu Val Gly Ser Arg Pro Cys Val Ser Thr Ala Gln 270 275 280 gat gag gcc aaa cac tcc cag gag cta cag tat gcc acc ccc gtg ttc 960 Asp Glu Ala Lys His Ser Gln Glu Leu Gln Tyr Ala Thr Pro Val Phe 285 290 295 cag gag gtg gca cca aga gag caa gaa gcc tgt gat tct tat aaa tct 1008 Gln Glu Val Ala Pro Arg Glu Gln Glu Ala Cys Asp Ser Tyr Lys Ser 300 305 310 315 gga tat gtc tat tct gaa ctc aac ttc tgaaatttac agaaacaaac 1055 Gly Tyr Val Tyr Ser Glu Leu Asn Phe 320 tacatctcag ggtaaggatg ctttttatga agctgatttc catgaacaaa aagcaaactt 1115 gaggctgagg cgggtggatc acagggtcag gagatcaaga ccatcctggc taacacgatg 1175 aaaccccgtc tctactaaaa aatacaaaaa ttagccaggt gtggtggtgt gtgtgtgtag 1235 tcccagctac tcgggaggct gaggcaggag aatcgcttga gcccgggagg cagaggttgc 1295 agtgagccaa gatcgtgcca ctgcactaca gcctgggcga caagagcaag acttcatctc 1355 aaaaaaaaaa aaaaa 1370 13 118 PRT Homo sapiens misc_feature Origin human embryonal liver-derived clone 0R087H 13 Met Arg Leu Phe Leu Trp Asn Ala Val Leu Thr Leu Phe Val Thr Ser -20 -15 -10 -5 Leu Ile Gly Ala Leu Ile Pro Glu Pro Glu Val Lys Ile Glu Val Leu -1 1 5 10 Gln Lys Pro Phe Ile Cys His Arg Lys Thr Lys Gly Gly Asp Leu Met 15 20 25 Leu Val His Tyr Glu Gly Tyr Leu Glu Lys Asp Gly Ser Leu Phe His 30 35 40 Ser Thr His Lys His Asn Asn Gly Gln Pro Ile Trp Phe Thr Leu Gly 45 50 55 60 Ile Leu Glu Ala Leu Lys Gly Trp Asp Gln Gly Leu Lys Gly Met Cys 65 70 75 Val Gly Glu Lys Arg Lys Leu Ile Ile Pro Pro Ala Leu Gly Tyr Gly 80 85 90 Lys Glu Gly Lys Val Phe 95 14 354 DNA Homo sapiens 14 atgaggcttt tcttgtggaa cgcggtcttg actctgttcg tcacttcttt gattggggct 60 ttgatccctg aaccagaagt gaaaattgaa gttctccaga agccattcat ctgccatcgc 120 aagaccaaag gaggggattt gatgttggtc cactatgaag gctacttaga aaaggacggc 180 tccttatttc actccactca caaacataac aatggtcagc ccatttggtt taccctgggc 240 atcctggagg ctctcaaagg ttgggaccag ggcttgaaag gaatgtgtgt aggagagaag 300 agaaagctca tcattcctcc tgctctgggc tatggaaaag aaggaaaagt cttt 354 15 1875 DNA Homo sapiens misc_feature Origin human embryonal liver-derived clone 0R087H 15 cctgaacttg tctgaagccc ttgtccgtaa gccttgaact acgttcttaa atctatgaag 60 tcgagggacc tttcgctgct tttgtaggga cttctttcct tgcttcagca ac atg agg 118 Met Arg -20 ctt ttc ttg tgg aac gcg gtc ttg act ctg ttc gtc act tct ttg att 166 Leu Phe Leu Trp Asn Ala Val Leu Thr Leu Phe Val Thr Ser Leu Ile -15 -10 -5 ggg gct ttg atc cct gaa cca gaa gtg aaa att gaa gtt ctc cag aag 214 Gly Ala Leu Ile Pro Glu Pro Glu Val Lys Ile Glu Val Leu Gln Lys -1 1 5 10 cca ttc atc tgc cat cgc aag acc aaa gga ggg gat ttg atg ttg gtc 262 Pro Phe Ile Cys His Arg Lys Thr Lys Gly Gly Asp Leu Met Leu Val 15 20 25 30 cac tat gaa ggc tac tta gaa aag gac ggc tcc tta ttt cac tcc act 310 His Tyr Glu Gly Tyr Leu Glu Lys Asp Gly Ser Leu Phe His Ser Thr 35 40 45 cac aaa cat aac aat ggt cag ccc att tgg ttt acc ctg ggc atc ctg 358 His Lys His Asn Asn Gly Gln Pro Ile Trp Phe Thr Leu Gly Ile Leu 50 55 60 gag gct ctc aaa ggt tgg gac cag ggc ttg aaa gga atg tgt gta gga 406 Glu Ala Leu Lys Gly Trp Asp Gln Gly Leu Lys Gly Met Cys Val Gly 65 70 75 gag aag aga aag ctc atc att cct cct gct ctg ggc tat gga aaa gaa 454 Glu Lys Arg Lys Leu Ile Ile Pro Pro Ala Leu Gly Tyr Gly Lys Glu 80 85 90 gga aaa gtc ttt tagtacatgc ttgcatgcct cttttggaaa gataccagtt 506 Gly Lys Val Phe 95 ttatcaacaa cctagcgcat gtcacatctc tgtctagatc tgaaatggta aaattccccc 566 agaaagtaca ctgatattta atattgatct cctggagatt cgaaatggac caagatccca 626 tgaatcattc caagaaatgg atcttaatga tgactggaaa ctctctaaag atgaggttaa 686 agcatattta aagaaggagt ttgaaaaaca tggtgcggtg gtgaatgaaa gtcatcatga 746 tgctttggtg gaggatattt ttgataaaga agatgaagac aaagatgggt ttatatctgc 806 cagagaattt acatataaac acgatgagtt atagagatac atctaccctt ttaatatagc 866 actcatcttt caagagaggg cagtcatctt taaagaacat tttattttta tacaatgttc 926 tttcttgctt tgttttttat ttttatatat tttttctgac tcctatttaa agaacccctt 986 aggtttctaa gtacccattt ctttctgata agttattggg aagaaaaagc taattggtct 1046 ttgaatagaa gacttctgga caatttttca ctttcacaga tatgaagctt tgttttactt 1106 tctcacttat aaatttaaaa tgttgcaact gggaatatac cacgacatga gaccaggtta 1166 tagcacaaat tagcacccta tatttctgct tccctctatt ttctccaagt tagaggtcaa 1226 catttgaaaa gccttttgca atagcccaag gcttgctatt ttcatgttat aatgaaatag 1286 tttatgtgta actggctctg agtctctgct tgaggaccag aggaaaatgg ttgttggacc 1346 tgacttgtta atggctactg ctttactaag gagatgtgca atgctgaagt tagaaacaag 1406 gttaatagcc aggcatggtg gctcatgcct gtaatcccag cactttggga ggctgaggcg 1466 ggcggatcac ctgaggttgg gagttcgaga ccagcctgac caacacggag aaaccctatc 1526 tctactaaaa atacaaaagt agccgggcgt ggtgatgcgt gcctgtaatc ccagctaccc 1586 aggaaggctg aggcggcaga atcacttgaa cccggaggcg gaggttgcgg taagccgaga 1646 tcacctccag cctggacact ctgtctcgaa aaaaagaaaa gaaacacggt taataacata 1706 taaatatgta tgcattgaga catgctacct aggacttaag ctgatgaagc ttggctccta 1766 gtgattggtg gcctattatg ataaatagga caaatcattt atgtgtgagt ttctttgtaa 1826 taaaatgtat caatatgtta aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 1875 16 377 PRT Homo sapiens misc_feature Origin human glioblastoma cell line T98G- derived clone 0A004FG 16 Met Asp Ser Ala Leu Ser Asp Pro His Asn Gly Ser Ala Glu Ala Gly 1 5 10 15 Gly Pro Thr Asn Ser Thr Thr Arg Pro Pro Ser Thr Pro Glu Gly Ile 20 25 30 Ala Leu Ala Tyr Gly Ser Leu Leu Leu Met Ala Leu Leu Pro Ile Phe 35 40 45 Phe Gly Ala Leu Arg Ser Val Arg Cys Ala Arg Gly Lys Asn Ala Ser 50 55 60 Asp Met Pro Glu Thr Ile Thr Ser Arg Asp Ala Ala Arg Phe Pro Ile 65 70 75 80 Ile Ala Ser Cys Thr Leu Leu Gly Leu Tyr Leu Phe Phe Lys Ile Phe 85 90 95 Ser Gln Glu Tyr Ile Asn Leu Leu Leu Ser Met Tyr Phe Phe Val Leu 100 105 110 Gly Ile Leu Ala Leu Ser His Thr Ile Ser Pro Phe Met Asn Lys Phe 115 120 125 Phe Pro Ala Ser Phe Pro Asn Arg Gln Tyr Gln Leu Leu Phe Thr Gln 130 135 140 Gly Ser Gly Glu Asn Lys Glu Glu Ile Ile Asn Tyr Glu Phe Asp Thr 145 150 155 160 Lys Asp Leu Val Cys Leu Gly Leu Ser Ser Ile Val Gly Val Trp Tyr 165 170 175 Leu Leu Arg Lys His Trp Ile Ala Asn Asn Leu Phe Gly Leu Ala Phe 180 185 190 Ser Leu Asn Gly Val Glu Leu Leu His Leu Asn Asn Val Ser Thr Gly 195 200 205 Cys Ile Leu Leu Gly Gly Leu Phe Ile Tyr Asp Val Phe Trp Val Phe 210 215 220 Gly Thr Asn Val Met Val Thr Val Ala Lys Ser Phe Glu Ala Pro Ile 225 230 235 240 Lys Leu Val Phe Pro Gln Asp Leu Leu Glu Lys Gly Leu Glu Ala Asn 245 250 255 Asn Phe Ala Met Leu Gly Leu Gly Asp Val Val Ile Pro Gly Ile Phe 260 265 270 Ile Ala Leu Leu Leu Arg Phe Asp Ile Ser Leu Lys Lys Asn Thr His 275 280 285 Thr Tyr Phe Tyr Thr Ser Phe Ala Ala Tyr Ile Phe Gly Leu Gly Leu 290 295 300 Thr Ile Phe Ile Met His Ile Phe Lys His Ala Gln Pro Ala Leu Leu 305 310 315 320 Tyr Leu Val Pro Ala Cys Ile Gly Phe Pro Val Leu Val Ala Leu Ala 325 330 335 Lys Gly Glu Val Thr Glu Met Phe Ser Tyr Glu Glu Ser Asn Pro Lys 340 345 350 Asp Pro Ala Ala Val Thr Glu Ser Lys Glu Gly Thr Glu Ala Ser Ala 355 360 365 Ser Lys Gly Leu Glu Lys Lys Glu Lys 370 375 17 1131 DNA Homo sapiens 17 atggactcgg ccctcagcga tccgcataac ggcagtgccg aggcaggcgg ccccaccaac 60 agcactacgc ggccgccttc cacgcccgag ggcatcgcgc tggcctacgg cagcctcctg 120 ctcatggcgc tgctgcccat cttcttcggc gccctgcgct ccgtacgctg cgcccgcggc 180 aagaatgctt cagacatgcc tgaaacaatc accagccggg atgccgcccg cttccccatc 240 atcgccagct gcacactctt ggggctctac ctctttttca aaatattctc ccaggagtac 300 atcaacctcc tgctgtccat gtatttcttc gtgctgggaa tcctggccct gtcccacacc 360 atcagcccct tcatgaataa gttttttcca gccagctttc caaatcgaca gtaccagctg 420 ctcttcacac agggttctgg ggaaaacaag gaagagatca tcaattatga atttgacacc 480 aaggacctgg tgtgcctggg cctgagcagc atcgttggcg tctggtacct gctgaggaag 540 cactggattg ccaacaacct ttttggcctg gccttctccc ttaatggagt agagctcctg 600 cacctcaaca atgtcagcac tggctgcatc ctgctgggcg gactcttcat ctacgatgtc 660 ttctgggtat ttggcaccaa tgtgatggtg acagtggcca agtccttcga ggcaccaata 720 aaattggtgt ttccccagga tctgctggag aaaggcctcg aagcaaacaa ctttgccatg 780 ctgggacttg gagatgtcgt cattccaggg atcttcattg ccttgctgct gcgctttgac 840 atcagcttga agaagaatac ccacacctac ttctacacca gctttgcagc ctacatcttc 900 ggcctgggcc ttaccatctt catcatgcac atcttcaagc atgctcagcc tgccctccta 960 tacctggtcc ccgcctgcat cggttttcct gtcctggtgg cgctggccaa gggagaagtg 1020 acagagatgt tcagttatga ggagtcaaat cctaaggatc cagcggcagt gacagaatcc 1080 aaagagggaa cagaggcatc agcatcgaag gggctggaga agaaagagaa a 1131 18 1612 DNA Homo sapiens misc_feature Origin human glioblastoma cell line T98G- derived clone 0A004FG 18 cacgtcactt cctgttgcct taggggaacg tggctttccc tgcagagccg gtgtctccgc 60 ctgcgtccct gctgcagcaa ccggagctgg agtcggatcc cgaacgcacc ctcgcc atg 119 Met 1 gac tcg gcc ctc agc gat ccg cat aac ggc agt gcc gag gca ggc ggc 167 Asp Ser Ala Leu Ser Asp Pro His Asn Gly Ser Ala Glu Ala Gly Gly 5 10 15 ccc acc aac agc act acg cgg ccg cct tcc acg ccc gag ggc atc gcg 215 Pro Thr Asn Ser Thr Thr Arg Pro Pro Ser Thr Pro Glu Gly Ile Ala 20 25 30 ctg gcc tac ggc agc ctc ctg ctc atg gcg ctg ctg ccc atc ttc ttc 263 Leu Ala Tyr Gly Ser Leu Leu Leu Met Ala Leu Leu Pro Ile Phe Phe 35 40 45 ggc gcc ctg cgc tcc gta cgc tgc gcc cgc ggc aag aat gct tca gac 311 Gly Ala Leu Arg Ser Val Arg Cys Ala Arg Gly Lys Asn Ala Ser Asp 50 55 60 65 atg cct gaa aca atc acc agc cgg gat gcc gcc cgc ttc ccc atc atc 359 Met Pro Glu Thr Ile Thr Ser Arg Asp Ala Ala Arg Phe Pro Ile Ile 70 75 80 gcc agc tgc aca ctc ttg ggg ctc tac ctc ttt ttc aaa ata ttc tcc 407 Ala Ser Cys Thr Leu Leu Gly Leu Tyr Leu Phe Phe Lys Ile Phe Ser 85 90 95 cag gag tac atc aac ctc ctg ctg tcc atg tat ttc ttc gtg ctg gga 455 Gln Glu Tyr Ile Asn Leu Leu Leu Ser Met Tyr Phe Phe Val Leu Gly 100 105 110 atc ctg gcc ctg tcc cac acc atc agc ccc ttc atg aat aag ttt ttt 503 Ile Leu Ala Leu Ser His Thr Ile Ser Pro Phe Met Asn Lys Phe Phe 115 120 125 cca gcc agc ttt cca aat cga cag tac cag ctg ctc ttc aca cag ggt 551 Pro Ala Ser Phe Pro Asn Arg Gln Tyr Gln Leu Leu Phe Thr Gln Gly 130 135 140 145 tct ggg gaa aac aag gaa gag atc atc aat tat gaa ttt gac acc aag 599 Ser Gly Glu Asn Lys Glu Glu Ile Ile Asn Tyr Glu Phe Asp Thr Lys 150 155 160 gac ctg gtg tgc ctg ggc ctg agc agc atc gtt ggc gtc tgg tac ctg 647 Asp Leu Val Cys Leu Gly Leu Ser Ser Ile Val Gly Val Trp Tyr Leu 165 170 175 ctg agg aag cac tgg att gcc aac aac ctt ttt ggc ctg gcc ttc tcc 695 Leu Arg Lys His Trp Ile Ala Asn Asn Leu Phe Gly Leu Ala Phe Ser 180 185 190 ctt aat gga gta gag ctc ctg cac ctc aac aat gtc agc act ggc tgc 743 Leu Asn Gly Val Glu Leu Leu His Leu Asn Asn Val Ser Thr Gly Cys 195 200 205 atc ctg ctg ggc gga ctc ttc atc tac gat gtc ttc tgg gta ttt ggc 791 Ile Leu Leu Gly Gly Leu Phe Ile Tyr Asp Val Phe Trp Val Phe Gly 210 215 220 225 acc aat gtg atg gtg aca gtg gcc aag tcc ttc gag gca cca ata aaa 839 Thr Asn Val Met Val Thr Val Ala Lys Ser Phe Glu Ala Pro Ile Lys 230 235 240 ttg gtg ttt ccc cag gat ctg ctg gag aaa ggc ctc gaa gca aac aac 887 Leu Val Phe Pro Gln Asp Leu Leu Glu Lys Gly Leu Glu Ala Asn Asn 245 250 255 ttt gcc atg ctg gga ctt gga gat gtc gtc att cca ggg atc ttc att 935 Phe Ala Met Leu Gly Leu Gly Asp Val Val Ile Pro Gly Ile Phe Ile 260 265 270 gcc ttg ctg ctg cgc ttt gac atc agc ttg aag aag aat acc cac acc 983 Ala Leu Leu Leu Arg Phe Asp Ile Ser Leu Lys Lys Asn Thr His Thr 275 280 285 tac ttc tac acc agc ttt gca gcc tac atc ttc ggc ctg ggc ctt acc 1031 Tyr Phe Tyr Thr Ser Phe Ala Ala Tyr Ile Phe Gly Leu Gly Leu Thr 290 295 300 305 atc ttc atc atg cac atc ttc aag cat gct cag cct gcc ctc cta tac 1079 Ile Phe Ile Met His Ile Phe Lys His Ala Gln Pro Ala Leu Leu Tyr 310 315 320 ctg gtc ccc gcc tgc atc ggt ttt cct gtc ctg gtg gcg ctg gcc aag 1127 Leu Val Pro Ala Cys Ile Gly Phe Pro Val Leu Val Ala Leu Ala Lys 325 330 335 gga gaa gtg aca gag atg ttc agt tat gag gag tca aat cct aag gat 1175 Gly Glu Val Thr Glu Met Phe Ser Tyr Glu Glu Ser Asn Pro Lys Asp 340 345 350 cca gcg gca gtg aca gaa tcc aaa gag gga aca gag gca tca gca tcg 1223 Pro Ala Ala Val Thr Glu Ser Lys Glu Gly Thr Glu Ala Ser Ala Ser 355 360 365 aag ggg ctg gag aag aaa gag aaa tgatgcggct ggtgcccgag cctctcaggg 1277 Lys Gly Leu Glu Lys Lys Glu Lys 370 375 ccagaccaga cagatggggg ctgggcccac acaggcgtgc accggtagag ggcacaggag 1337 gccaagggca gctccaggac agggcagggg gcagcaggat acctccagcc aggcctctgt 1397 ggcctctgtt tccttctccc tttcttggcc ctcctctgct cctccccaca ccctgcaggc 1457 aaaagaaacc cccagcttcc cccctccccg ggagccaggt gggaaaagtg ggtgtgattt 1517 ttagattttg tattgtggac tgattttgcc tcacattaaa aactcatccc atggccaggg 1577 cgggccactg tgctcctgaa aaaaaaaaaa aaaaa 1612 19 377 PRT Homo sapiens misc_feature Origin human glioblastoma cell line T98G- derived clone 0A004LD 19 Met Asp Ser Ala Leu Ser Asp Pro His Asn Gly Ser Ala Glu Ala Gly 1 5 10 15 Gly Pro Thr Asn Ser Thr Thr Arg Pro Pro Ser Thr Pro Glu Gly Ile 20 25 30 Ala Leu Ala Tyr Gly Ser Leu Leu Leu Met Ala Leu Leu Pro Ile Phe 35 40 45 Phe Gly Ala Leu Arg Ser Val Arg Cys Ala Arg Gly Lys Asn Ala Ser 50 55 60 Asp Met Pro Glu Thr Ile Thr Ser Arg Asp Ala Ala Arg Phe Pro Ile 65 70 75 80 Ile Ala Ser Cys Thr Leu Leu Gly Leu Tyr Leu Phe Phe Lys Ile Phe 85 90 95 Ser Gln Glu Tyr Ile Asn Leu Leu Leu Ser Met Tyr Phe Phe Val Leu 100 105 110 Gly Ile Leu Ala Leu Ser His Thr Ile Ser Pro Phe Met Asn Lys Phe 115 120 125 Phe Pro Ala Ser Leu Pro Asn Arg Gln Tyr Gln Leu Leu Phe Thr Gln 130 135 140 Gly Ser Gly Glu Asn Lys Glu Glu Ile Ile Asn Tyr Glu Phe Asp Thr 145 150 155 160 Lys Asp Leu Val Cys Leu Gly Leu Ser Ser Ile Val Asp Val Trp Tyr 165 170 175 Leu Leu Arg Lys His Trp Ile Ala Asn Asn Leu Phe Gly Leu Ala Phe 180 185 190 Ser Leu Asn Gly Val Glu Leu Leu His Leu Asn Asn Val Ser Thr Gly 195 200 205 Cys Ile Leu Leu Gly Gly Leu Phe Ile Tyr Asp Val Phe Trp Val Phe 210 215 220 Gly Thr Asn Val Met Val Thr Val Ala Lys Ser Phe Glu Ala Pro Ile 225 230 235 240 Lys Leu Val Phe Pro Gln Asp Leu Leu Glu Lys Gly Leu Glu Ala Asn 245 250 255 Asn Phe Ala Met Leu Gly Leu Gly Asp Val Val Ile Pro Gly Ile Phe 260 265 270 Ile Ala Leu Leu Leu Arg Phe Asp Ile Ser Leu Lys Lys Asn Thr His 275 280 285 Thr Tyr Phe Tyr Thr Ser Phe Ala Ala Tyr Ile Phe Gly Leu Gly Leu 290 295 300 Thr Ile Phe Ile Met His Ile Phe Lys His Ala Gln Pro Ala Leu Leu 305 310 315 320 Tyr Leu Val Pro Ala Cys Ile Gly Phe Pro Val Leu Val Ala Leu Ala 325 330 335 Lys Gly Glu Val Thr Glu Met Phe Ser Tyr Glu Glu Ser Asn Pro Lys 340 345 350 Asp Pro Ala Ala Val Thr Glu Ser Lys Glu Gly Thr Glu Ala Ser Ala 355 360 365 Ser Lys Gly Leu Glu Lys Lys Glu Lys 370 375 20 1131 DNA Homo sapiens 20 atggactcgg ccctcagcga tccgcataac ggcagtgccg aggcaggcgg ccccaccaac 60 agcactacgc ggccgccttc cacgcccgag ggcatcgcgc tggcctacgg cagcctcctg 120 ctcatggcgc tgctgcccat cttcttcggc gccctgcgct ccgtacgctg cgcccgcggc 180 aagaatgctt cagacatgcc tgaaacaatc accagccggg atgccgcccg cttccccatc 240 atcgccagct gcacactctt ggggctctac ctctttttca aaatattctc ccaggagtac 300 atcaacctcc tgctgtccat gtatttcttc gtgctgggaa tcctggccct gtcccacacc 360 atcagcccct tcatgaataa gttttttcca gccagccttc caaatcgaca gtaccagctg 420 ctcttcacac agggttctgg ggaaaacaag gaagagatca tcaattatga atttgacacc 480 aaggacctgg tgtgcctggg cctgagcagc atcgttgacg tctggtacct gctgaggaag 540 cactggattg ccaacaacct ttttggcctg gccttctccc ttaatggagt agagctcctg 600 cacctcaaca atgtcagcac tggctgcatc ctgctgggcg gactcttcat ctacgatgtc 660 ttctgggtat ttggcaccaa tgtgatggtg acagtggcca agtccttcga ggcaccaata 720 aaattggtgt ttccccagga tctgctggag aaaggcctcg aagcaaacaa ctttgccatg 780 ctgggacttg gagatgtcgt cattccaggg atcttcattg ccttgctgct gcgctttgac 840 atcagcttga agaagaatac ccacacctac ttctacacca gctttgcagc ctacatcttc 900 ggcctgggcc ttaccatctt catcatgcac atcttcaagc atgctcagcc tgccctccta 960 tacctggtcc ccgcctgcat cggttttcct gtcctggtgg cgctggccaa gggagaagtg 1020 acagagatgt tcagttatga ggagtcaaat cctaaggatc cagcggcagt gacagaatcc 1080 aaagagggaa cagaggcatc agcatcgaag gggctggaga agaaagagaa a 1131 21 1612 DNA Homo sapiens misc_feature Origin human glioblastoma cell line T98G- derived clone 0A004LD 21 cacgtcactt cctgttgcct taggggaacg tggctttccc tgcagagccg gtgtctccgc 60 ctgcgtccct gctgcagcaa ccggagctgg agtcggatcc cgaacgcacc ctcgcc atg 119 Met 1 gac tcg gcc ctc agc gat ccg cat aac ggc agt gcc gag gca ggc ggc 167 Asp Ser Ala Leu Ser Asp Pro His Asn Gly Ser Ala Glu Ala Gly Gly 5 10 15 ccc acc aac agc act acg cgg ccg cct tcc acg ccc gag ggc atc gcg 215 Pro Thr Asn Ser Thr Thr Arg Pro Pro Ser Thr Pro Glu Gly Ile Ala 20 25 30 ctg gcc tac ggc agc ctc ctg ctc atg gcg ctg ctg ccc atc ttc ttc 263 Leu Ala Tyr Gly Ser Leu Leu Leu Met Ala Leu Leu Pro Ile Phe Phe 35 40 45 ggc gcc ctg cgc tcc gta cgc tgc gcc cgc ggc aag aat gct tca gac 311 Gly Ala Leu Arg Ser Val Arg Cys Ala Arg Gly Lys Asn Ala Ser Asp 50 55 60 65 atg cct gaa aca atc acc agc cgg gat gcc gcc cgc ttc ccc atc atc 359 Met Pro Glu Thr Ile Thr Ser Arg Asp Ala Ala Arg Phe Pro Ile Ile 70 75 80 gcc agc tgc aca ctc ttg ggg ctc tac ctc ttt ttc aaa ata ttc tcc 407 Ala Ser Cys Thr Leu Leu Gly Leu Tyr Leu Phe Phe Lys Ile Phe Ser 85 90 95 cag gag tac atc aac ctc ctg ctg tcc atg tat ttc ttc gtg ctg gga 455 Gln Glu Tyr Ile Asn Leu Leu Leu Ser Met Tyr Phe Phe Val Leu Gly 100 105 110 atc ctg gcc ctg tcc cac acc atc agc ccc ttc atg aat aag ttt ttt 503 Ile Leu Ala Leu Ser His Thr Ile Ser Pro Phe Met Asn Lys Phe Phe 115 120 125 cca gcc agc ctt cca aat cga cag tac cag ctg ctc ttc aca cag ggt 551 Pro Ala Ser Leu Pro Asn Arg Gln Tyr Gln Leu Leu Phe Thr Gln Gly 130 135 140 145 tct ggg gaa aac aag gaa gag atc atc aat tat gaa ttt gac acc aag 599 Ser Gly Glu Asn Lys Glu Glu Ile Ile Asn Tyr Glu Phe Asp Thr Lys 150 155 160 gac ctg gtg tgc ctg ggc ctg agc agc atc gtt gac gtc tgg tac ctg 647 Asp Leu Val Cys Leu Gly Leu Ser Ser Ile Val Asp Val Trp Tyr Leu 165 170 175 ctg agg aag cac tgg att gcc aac aac ctt ttt ggc ctg gcc ttc tcc 695 Leu Arg Lys His Trp Ile Ala Asn Asn Leu Phe Gly Leu Ala Phe Ser 180 185 190 ctt aat gga gta gag ctc ctg cac ctc aac aat gtc agc act ggc tgc 743 Leu Asn Gly Val Glu Leu Leu His Leu Asn Asn Val Ser Thr Gly Cys 195 200 205 atc ctg ctg ggc gga ctc ttc atc tac gat gtc ttc tgg gta ttt ggc 791 Ile Leu Leu Gly Gly Leu Phe Ile Tyr Asp Val Phe Trp Val Phe Gly 210 215 220 225 acc aat gtg atg gtg aca gtg gcc aag tcc ttc gag gca cca ata aaa 839 Thr Asn Val Met Val Thr Val Ala Lys Ser Phe Glu Ala Pro Ile Lys 230 235 240 ttg gtg ttt ccc cag gat ctg ctg gag aaa ggc ctc gaa gca aac aac 887 Leu Val Phe Pro Gln Asp Leu Leu Glu Lys Gly Leu Glu Ala Asn Asn 245 250 255 ttt gcc atg ctg gga ctt gga gat gtc gtc att cca ggg atc ttc att 935 Phe Ala Met Leu Gly Leu Gly Asp Val Val Ile Pro Gly Ile Phe Ile 260 265 270 gcc ttg ctg ctg cgc ttt gac atc agc ttg aag aag aat acc cac acc 983 Ala Leu Leu Leu Arg Phe Asp Ile Ser Leu Lys Lys Asn Thr His Thr 275 280 285 tac ttc tac acc agc ttt gca gcc tac atc ttc ggc ctg ggc ctt acc 1031 Tyr Phe Tyr Thr Ser Phe Ala Ala Tyr Ile Phe Gly Leu Gly Leu Thr 290 295 300 305 atc ttc atc atg cac atc ttc aag cat gct cag cct gcc ctc cta tac 1079 Ile Phe Ile Met His Ile Phe Lys His Ala Gln Pro Ala Leu Leu Tyr 310 315 320 ctg gtc ccc gcc tgc atc ggt ttt cct gtc ctg gtg gcg ctg gcc aag 1127 Leu Val Pro Ala Cys Ile Gly Phe Pro Val Leu Val Ala Leu Ala Lys 325 330 335 gga gaa gtg aca gag atg ttc agt tat gag gag tca aat cct aag gat 1175 Gly Glu Val Thr Glu Met Phe Ser Tyr Glu Glu Ser Asn Pro Lys Asp 340 345 350 cca gcg gca gtg aca gaa tcc aaa gag gga aca gag gca tca gca tcg 1223 Pro Ala Ala Val Thr Glu Ser Lys Glu Gly Thr Glu Ala Ser Ala Ser 355 360 365 aag ggg ctg gag aag aaa gag aaa tgatgcggct ggtgcccgag cctctcaggg 1277 Lys Gly Leu Glu Lys Lys Glu Lys 370 375 ccagaccaga cagatggggg ctgggcccac acaggcgtgc accggtagag ggcacaggag 1337 gccaagggca gctccaggac agggcagggg gcagcaggat acctccagcc aggcctctgt 1397 ggcctctgtt tccttctccc tttcttggcc ctcctctgct cctccccaca ccctgcaggc 1457 aaaagaaacc cccagcttcc cccctccccg ggagccaggt gggaaaagtg ggtgtgattt 1517 ttagattttg tattgtggac tgattttgcc tcacattaaa aactcatccc atggccaggg 1577 cgggccactg tgctcctgaa aaaaaaaaaa aaaaa 1612 22 35 DNA Artificial Sequence Primer 22 cgattgaatt ctagacctgc ctcgagnnnn nnnnn 35 23 27 DNA Artificial Sequence Primer 0M007-F3 23 aactgcagat cttgggactc atcagcc 27 24 28 DNA Artificial Sequence Primer 0M007-F2 24 aagaggacat tgttttcatc atggatgc 28 25 27 DNA Artificial Sequence Primer 0MB096-F1 25 acaacatgca ccaccagtgg cttctgc 27 26 28 DNA Artificial Sequence Primer 0AF038-F1 26 agaatgtgga gccatttgaa caggctcc 28 27 27 DNA Artificial Sequence Primer 0R087H-F1 27 tgaagccctt gtccgtaagc cttgaac 27 28 24 DNA Artificial Sequence Primer 0A004-F1 28 atgcacatct tcaagcatgc tcag 24 

1. A polypeptide in substantially purified form comprising the amino acid sequence shown in SEQ ID NO. 1, 4, 7, 10, 13, 16 or 19, a homologue thereof, a fragment thereof, or a homologue of the fragment.
 2. The polypeptide according to claim 1, comprising the amino acid sequence shown in SEQ ID NOs: 1, 4, 7, 10, 13, 16 or
 19. 3. A cDNA encoding the polypeptide according to claim
 1. 4. The cDNA according to claim 3, comprising the nucleotide sequence shown in SEQ ID NOs: 2, 5, 8, 11, 14, 17 or 20, or a fragment cDNA selectively hybridized to the sequence.
 5. The cDNA according to claim 3, comprising the nucleotide sequence shown in SEQ ID NOs: 3, 6, 9, 12, 15, 18 or 21, or a fragment cDNA selectively hybridized to the sequence.
 6. A replication or expression vector carrying the cDNA according to any one of claims 3 to
 5. 7. A host cell transformed with the replication or expression vector according to claim
 6. 8. A method for producing the polypeptide according to claim 1 or 2 which comprises culturing a host cell according to claim 7 under conditions effective to express the polypeptide according to claim 1 or
 2. 9. A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or
 2. 10. A pharmaceutical composition comprising the polypeptide according to claim 1 or 2 or the antibody according to claim 9, and a pharmaceutically acceptable diluent and/or carrier. 